Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             604 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 1.198A Brain acetylcholinesterase changes in Dementia with Lewy Bodies and Parkinson's disease with Dementia demonstrated by PET Shimada, H.
2007
13 S2 p. S59-
1 p.
artikel
2 1.148a Cardiac sympathetic denervation is early and progressive in Lewy body disease Burnett, M.
2007
13 S2 p. S46-
1 p.
artikel
3 1.317 A case that has been diagnosed as cirrhosis after the emergence of parkinsonism symptoms Turkmen, C.
2007
13 S2 p. S81-
1 p.
artikel
4 2.411 A comparison of the effects of intrastriatal and intranigral administration of the selective proteasome inhibitor lactacystin on the biochemical markers of Parkinson's disease Lorenc-Koci, E.
2007
13 S2 p. S130-
1 p.
artikel
5 3.502 A comprehensive model of health-related quality of life in Parkinson's disease: Challenges for patient management Visser, M.
2007
13 S2 p. S187-S188
2 p.
artikel
6 3.403 Activity and participation on Parkinson's disease Nickel, R.
2007
13 S2 p. S180-S181
2 p.
artikel
7 3.106 Additional value of SPECT imaging in comparison with clinical diagnosis in 248 patients with parkinsonism Vlaar, A.
2007
13 S2 p. S154-
1 p.
artikel
8 2.262 Adherence to antiparkinson medication in a multi-centre European study. Grosset, D.
2007
13 S2 p. S115-
1 p.
artikel
9 2.257 A double blind placebo controlled study of modafinil for Parkinson's disease related fatigue Tyne, H.
2007
13 S2 p. S113-S114
2 p.
artikel
10 1.022 Adult onset dystonic tremor as differential diagnosis for Parkinson's disease: Detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function Schwingenschuh, P.
2007
13 S2 p. S33-
1 p.
artikel
11 1.278 Adult onset dystonic tremor as differential diagnosis for Parkinson's disease: Detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function Schwingenschuh, P.
2007
13 S2 p. S70-S71
2 p.
artikel
12 1.120 Advanced screening tools in day-to-day movement disorders observed in ambulatory assistance Echebarria, S.G.
2007
13 S2 p. S38-S39
2 p.
artikel
13 3.401 A DVD with home exercises and movement advice for patients with Parkinson's disease van Wegen, E.E.H.
2007
13 S2 p. S180-
1 p.
artikel
14 2.249A Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) Ebersbach, G.
2007
13 S2 p. S111-
1 p.
artikel
15 3.241A Increased beta activity in dystonia patients after drug-induced dopamine deficiency Kühn, A.
2007
13 S2 p. S173-
1 p.
artikel
16 2.313 Alcoholism, alpha-synuclein, and Parkinson disease: A case-control study Brighina, L.
2007
13 S2 p. S125-
1 p.
artikel
17 2.217 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease Brotchie, J.
2007
13 S2 p. S102-
1 p.
artikel
18 2.447 AMPA antagonists attenuate L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat model of Parkinson's disease Kobylecki, C.
2007
13 S2 p. S140-
1 p.
artikel
19 2.107 Analysis of the PARK2 mutations in Polish early onset Parkinson's disease patients Koziorowski, D.
2007
13 S2 p. S93-S94
2 p.
artikel
20 1.118 An automated system for early and differential diagnostics of the clinical forms of Parkinson's disease Khutorskaya, O.
2007
13 S2 p. S38-
1 p.
artikel
21 2.438 A neuroprotective role for cerebrolysin in a rotenone model of Parkinson's disease Stoica, R.
2007
13 S2 p. S137-S138
2 p.
artikel
22 2.420 An improved model of L-DOPA-induced dyskinesia in 6-OHDA lesioned rats Spinnewyn, B.
2007
13 S2 p. S132-S133
2 p.
artikel
23 2.258 An observational study to evaluate the association between quality of life scores and medication changes in Parkinson's disease Roberts, H.
2007
13 S2 p. S114-
1 p.
artikel
24 2.109 A novel function of parkin as a transcriptional repressor of the oncogene p53 and its impairment by familial associated Parkinson's disease mutations Alves da Costa, C.
2007
13 S2 p. S94-
1 p.
artikel
25 2.219 A pharmacokinetic–pharmacodynamic model for duodenal levodopa infusion Westin, J.
2007
13 S2 p. S102-S103
2 p.
artikel
26 1.208 APOE, CYP46, PRNP and PRND: Genetic polymorphisms in Alzheimer's Disease and mild cognitive impairment Flirski, M.
2007
13 S2 p. S62-
1 p.
artikel
27 3.312 Application of a variable, upgradeable, individually adjustable training device in disorders of balance and gait associated with Parkinson's disease Raabe-Oetker, A.
2007
13 S2 p. S178-S179
2 p.
artikel
28 3.406 A process evaluation of ParkNet implementation Munneke, M.
2007
13 S2 p. S181-
1 p.
artikel
29 2.421 A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease Pienaar, I.
2007
13 S2 p. S133-
1 p.
artikel
30 2.020 A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease Pienaar, I.
2007
13 S2 p. S91-
1 p.
artikel
31 1.179 A rating instrument for hallucinations in Parkinson's disease: The University of Miami Hallucinations Questionnaire (UMHQ.v2) Papapetropoulos, S.
2007
13 S2 p. S54-
1 p.
artikel
32 1.106 Are brain networks changed in Parkinson's disease? A graph theoretical analysis of resting-state magneto-encephalographic functional connectivity Stoffers, D.
2007
13 S2 p. S35-
1 p.
artikel
33 1.128 Are there multisensory defcits in early Parkinson's disease? A case-control study Pieri, V.
2007
13 S2 p. S40-S41
2 p.
artikel
34 3.242 Arguments for and against rTMS therapy in Parkinson's disease and syndrome Màlly, J.
2007
13 S2 p. S173-
1 p.
artikel
35 2.279 Aripiprazole in L-Dopa induced dyskinesias (LID): One year open study Meco, G.
2007
13 S2 p. S119-
1 p.
artikel
36 2.113 A role for PINK1 in mitochondrial dynamics and mitochondrial function Paesen, K.
2007
13 S2 p. S95-
1 p.
artikel
37 2.263 Assessment of drug–drug interaction potential among patients with Parkinson's disease Montejano, L.
2007
13 S2 p. S115-
1 p.
artikel
38 3.307 Assessment of spatio-temporal gait parameters with an ambulatory gait monitor in patients with Parkinson's disease Speelman, A.
2007
13 S2 p. S177-
1 p.
artikel
39 2.110 Association of PARKIN gene polymorphisms with Parkinson's disease in the Russian population Demchuk, N.
2007
13 S2 p. S94-
1 p.
artikel
40 1.019 Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes Soma, H.
2007
13 S2 p. S32-
1 p.
artikel
41 1.209 Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes Soma, H.
2007
13 S2 p. S62-
1 p.
artikel
42 1.104 Associations between Parkinson disease and putatively protective factors Bolokadze, L.
2007
13 S2 p. S34-S35
2 p.
artikel
43 3.022 Associations between the use of cueing specific guidelines and gait in Parkinson's disease: The RESCUE trial Lim, I.
2007
13 S2 p. S151-S152
2 p.
artikel
44 3.314 Associations between the use of cueing specific guidelines and gait in Parkinson's disease: The RESCUE trial Lim, I.
2007
13 S2 p. S179-
1 p.
artikel
45 2.445 A summary of the in vitro pharmacology of pardoprunox (SLV308): A novel dopamine D2/D3 partial agonist and 5-HT1A agonist for the treatment of Parkinson's disease McCreary, A.
2007
13 S2 p. S139-S140
2 p.
artikel
46 1.215 Atherosclerotic changes of the extracranial part of carotid vessels at patients with vascular parkinsonism Butkovic Soldo, S.
2007
13 S2 p. S64-
1 p.
artikel
47 Author Index 2007
13 S2 p. S195-S204
10 p.
artikel
48 1.149 Autonomic dysfunction in Parkinson's disease and spinocerebellar ataxia: A pilot study Farnikova, K.
2007
13 S2 p. S46-
1 p.
artikel
49 2.306 A yeast-based screening system for mouse brain proteins that modify the toxicity of alpha-synuclein de Graeve, S.
2007
13 S2 p. S123-
1 p.
artikel
50 3.302 Balance performance and fall incidents in persons with Parkinson's disease Kerckhofs, E.
2007
13 S2 p. S175-S176
2 p.
artikel
51 2.450 Beneficial effects of the new multitargeting molecules BN82451 and BN83026 on tardive dyskinesia induced by haloperidol in rats Auguet, M.
2007
13 S2 p. S141-
1 p.
artikel
52 1.292 Beneficial impact of pramipexole on social functioning in patients with restless legs syndrome Zesiewicz, T.
2007
13 S2 p. S74-
1 p.
artikel
53 1.115 Benign tremulous parkinsonism: Clinical and pathological study Rajput, A.
2007
13 S2 p. S37-S38
2 p.
artikel
54 3.232 Bilateral effects of unilateral deep brain stimulation Kovacs, N.
2007
13 S2 p. S170-
1 p.
artikel
55 1.150 Bladder and voiding dysfunction in Parkinson's disease: A study with the overactive bladder questionnaire in a cohort of patients with Parkinson's disease Meco, G.
2007
13 S2 p. S46-
1 p.
artikel
56 2.446 BN82451 and BN83026 reduce L-DOPA-induced dyskinesia in hemiparkinsonian rats Spinnewyn, B.
2007
13 S2 p. S140-
1 p.
artikel
57 3.311 Bobbing gait responsive to ropinerole: An atypical Parkisonism? Alvarez, M.
2007
13 S2 p. S178-
1 p.
artikel
58 1.157 Body mass index is reduced in Parkinson's disease Adwan, Z.
2007
13 S2 p. S48-
1 p.
artikel
59 3.219 Body weight and body mass index changes after subthalamic nucleus deep brain stimulation in Parkinson's disease Kim, S.-R.
2007
13 S2 p. S166-S167
2 p.
artikel
60 1.502 Body weight & Parkinson's disease Bachmann, C.
2007
13 S2 p. S84-
1 p.
artikel
61 4.005 Botulinum toxin Truong, D.
2007
13 S2 p. S193-
1 p.
artikel
62 1.310 Botulinum toxin type A in simple motor tics: Analysis of long-term treatment Rath, J.
2007
13 S2 p. S79-
1 p.
artikel
63 1.017 Brain acetylcholinesterase changes in Dementia with Lewy Bodies and Parkinson's disease with Dementia demonstrated by PET Shimada, H.
2007
13 S2 p. S31-S32
2 p.
artikel
64 3.104 Brain regions involved in a response conflict task in patients with Parkinson's disease Rektorova, I.
2007
13 S2 p. S153-S154
2 p.
artikel
65 3.231 Brain stimulation in Parkinson disease Fedotova, I.
2007
13 S2 p. S170-
1 p.
artikel
66 3.128 Cardiac metaiodobenzylguanidine scintigraphy as a peripheral biomarker for the diagnosis of Parkinson's disease Sawada, H.
2007
13 S2 p. S160-
1 p.
artikel
67 1.012 Cardiac sympathetic denervation is early and progressive in Lewy body disease Burnett, M.
2007
13 S2 p. S30-
1 p.
artikel
68 3.424 Caregiver strain in Parkinson's disease Kerckhofs, E.
2007
13 S2 p. S186-
1 p.
artikel
69 2.206 Carnosine increases efficiency of L-DOPA therapy of parkinsonics Boldyrev, A.
2007
13 S2 p. S99-
1 p.
artikel
70 3.301 Causes of falls in retrospective and prospective study in Parkinson's disease patients Rudzińska, M.
2007
13 S2 p. S175-
1 p.
artikel
71 2.452 CD4+ anti-MOG lymphocytes administration improves recovery after MPTP induced injury in mice model of Parkinson's disease Kurkowska-Jastrzebska, I.
2007
13 S2 p. S141-S142
2 p.
artikel
72 2.106 Cellular and biochemical study of LRRK2 ROC GTPase domain Daniëls, V.
2007
13 S2 p. S93-
1 p.
artikel
73 2.013 Cellular and biochemical study of LRRK2 ROC GTPase domain Daniëls, V.
2007
13 S2 p. S89-
1 p.
artikel
74 1.322 Cerebellar ataxia in a young patient as the first manifestation of Alexander's Disease Munhoz, R.
2007
13 S2 p. S82-
1 p.
artikel
75 1.280 Cerebellar hemorrhage modifies essential tremor Rajput, A.
2007
13 S2 p. S71-
1 p.
artikel
76 3.115 Cerebral glucose metabolism in Parkinson's disease with Dementia Ma, A.
2007
13 S2 p. S157-
1 p.
artikel
77 1.250 Cervical dystonia due to cerebellar stroke Habek, M.
2007
13 S2 p. S65-
1 p.
artikel
78 1.257 Cervical dystonia: Effect of botulinum toxin on trajectory formation Pelosin, E.
2007
13 S2 p. S67-
1 p.
artikel
79 3.103 Change of the midbrain size in normal aging and progressive supranuclear palsy: An MRI study Sung, Y.-H.
2007
13 S2 p. S153-
1 p.
artikel
80 1.144 Changes in sexual interest and function in patients with Parkinson's disease: Focus on hypersexuality Naidu, Y.
2007
13 S2 p. S44-S45
2 p.
artikel
81 3.247 Changes of excitability in contralateral motor cortex after paired associative stimulation: An evidence of intermanual transfer Shin, H.-W.
2007
13 S2 p. S175-
1 p.
artikel
82 2.453 Characterisation of the Akt–PTEN signal transduction pathway, and its relationship with DJ-1 and PINK1 signalling, in the normal and Parkinson's disease substantia nigra Timmons, S.
2007
13 S2 p. S142-
1 p.
artikel
83 2.407 Characterization of lentiviral vector mediated gene transfer and expression in organotypic ventral mesencephalic cultures from foetal mice Rossen, S.
2007
13 S2 p. S129-
1 p.
artikel
84 2.308 Characterization of the expression of alpha-synuclein and suppressor/enhancer proteins in Saccharomyces cerevisiae Marinelli, S.
2007
13 S2 p. S123-S124
2 p.
artikel
85 1.308 Chorea as a initial manifestation of Polycythemia vera Lee, J.E.
2007
13 S2 p. S78-S79
2 p.
artikel
86 3.236 Chronic deep brain stimulation of the subthalamic nucleus increases striatal tissue levels of dopamine in naive rats Harnack, D.
2007
13 S2 p. S171-S172
2 p.
artikel
87 2.201 Classical neurotransmitters and neuropeptides involved in Parkinson's disease Werner, F.-M.
2007
13 S2 p. S97-
1 p.
artikel
88 1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome Bakker, S.
2007
13 S2 p. S72-
1 p.
artikel
89 1.309 Clinical and molecular studies of patients screened for Huntington's disease in a movement disorders clinic from Brazil Riccioppo, G.
2007
13 S2 p. S79-
1 p.
artikel
90 1.262 Clinical characteristics and causative gene of Dopa-responsive dystonia Chen, L.
2007
13 S2 p. S68-
1 p.
artikel
91 1.314 Clinical characteristics of 49 patients with psychogenic movement disorders in a tertiary clinic in Turkey Ozekmekci, S.
2007
13 S2 p. S80-
1 p.
artikel
92 1.252 Clinical characterization of a large Dutch family with primary focal dystonia Contarino, M.F.
2007
13 S2 p. S65-S66
2 p.
artikel
93 1.321 Clinical relevance of “bulging eyes” for the differential diagnosis of spinocerebellar ataxias Teive, H.
2007
13 S2 p. S82-
1 p.
artikel
94 2.117 Clinical spectrum of a large Sardinian family with Parkinson's disease Cossu, G.
2007
13 S2 p. S96-
1 p.
artikel
95 2.003 Clinimetrics van Hilten, J.J.
2007
13 S2 p. S87-
1 p.
artikel
96 2.022 Cognitive and locomotor deficits accompanied by congophilic aggregate formation in the Drosophila model for defective actin remodeling Molotkov, D.
2007
13 S2 p. S91-S92
2 p.
artikel
97 2.418 Cognitive and locomotor deficits accompanied by congophilic aggregate formation in the Drosophila model for defective actin remodeling Molotkov, D.
2007
13 S2 p. S132-
1 p.
artikel
98 1.187 Cognitive dysfunction in Nigerian patients with Parkinson's disease Akinyemi, R.
2007
13 S2 p. S56-
1 p.
artikel
99 1.300 Cognitive impairments as diagnostic markers for ADHD: An overview Gupta, R.
2007
13 S2 p. S76-
1 p.
artikel
100 1.184 Cognitive impairments in patients with early Parkinson's disease Dokova, Y.
2007
13 S2 p. S55-
1 p.
artikel
101 1.196 Cognitive potentials in the basal ganglia Rektor, I.
2007
13 S2 p. S58-S59
2 p.
artikel
102 3.108 Combined [123I]FP-CIT SPECT and 99mTc-HMPAO SPECT for the diagnosis of dementia with Lewy bodies Mendonça Silva, N.M.
2007
13 S2 p. S155-
1 p.
artikel
103 Committees 2007
13 S2 p. xi-xii
nvt p.
artikel
104 1.107 Comparing computer-assisted 3D reconstructions of the human substantia nigra with disector stereology Tenenholz Grinberg, L.
2007
13 S2 p. S35-
1 p.
artikel
105 1.266 Comparison of the Extensor-digitorum-brevis test (EDB) vs mouse diaphragm assay (MDA) as indirect test methods for detection of Botulinum-toxin A (BTXA) antibodies García, A.
2007
13 S2 p. S69-
1 p.
artikel
106 3.240 Comparison of unilateral pallidotomy versus subthalamotomy in advanced idiopathic Parkinson's disease Hanagasi, H.
2007
13 S2 p. S172-S173
2 p.
artikel
107 3.427 Compliance to treatment for dysphagia in patients with Parkinson's disease Peretz, C.
2007
13 S2 p. S187-
1 p.
artikel
108 1.189 Components and patterns of self-efficacy in Parkinson's disease patients Sgaramella, T.M.
2007
13 S2 p. S56-S57
2 p.
artikel
109 Contents 2007
13 S2 p. vii-
1 p.
artikel
110 2.250 Continuous dopaminergic stimulation (CDS) with lisuride improves the therapy of Parkinson's disease Horowski, R.
2007
13 S2 p. S111-S112
2 p.
artikel
111 2.222 Continuous dopaminergic stimulation in advanced PD. Switching from apomorphine to duodopa: Which treatment is better? Tamburin, S.
2007
13 S2 p. S103-
1 p.
artikel
112 2.227 Continuous dopaminergic stimulation in Parkinson's disease: Comparison of new methods of drug delivery by measuring dopamine metabolites concentrations in plasma Saurugg, R.
2007
13 S2 p. S105-
1 p.
artikel
113 1.142 Correlation between depression and sleep disability in parkinsonian patient Sani, A.F.
2007
13 S2 p. S44-
1 p.
artikel
114 1.174 Correlation between severity of Parkinson's disease (according to Hoehn–Yahr) and depression in Parkinson's disease (Hamilton Depression Rating Scale) Sani, A.F.
2007
13 S2 p. S53-
1 p.
artikel
115 1.122 Course of akinetic/rigid and tremor dominant Parkinson's disease Rajput, A.
2007
13 S2 p. S39-
1 p.
artikel
116 3.412 Current practice in occupational therapy for patients with Parkinson's disease Sturkenboom, I.
2007
13 S2 p. S183-
1 p.
artikel
117 1.284 Daytime fatigue in idiopathic restless legs syndrome: Evaluation with Parkinson's fatigue scale Naidu, Y.
2007
13 S2 p. S72-
1 p.
artikel
118 3.215 Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: Clinical follow-up of 55 patients Ramat, S.
2007
13 S2 p. S165-S166
2 p.
artikel
119 1.177 Dementia and depression in Parkinson's disease Sinanovic, O.
2007
13 S2 p. S53-
1 p.
artikel
120 2.322 Demonstration of the formation of Lewy bodies in parkinsonism from disrupted neurotransmitter-storage organelles and their interaction with alpha-synuclein Chrysanthou, M.
2007
13 S2 p. S127-
1 p.
artikel
121 1.285 Depression or restless leg syndrome: Diagnostic difficulties (case report) Flirski, M.
2007
13 S2 p. S72-
1 p.
artikel
122 1.108 Depression presenting before motor manifestation of Parkinson's disease: Impact on motor and cognitive features Klepac, N.
2007
13 S2 p. S35-S36
2 p.
artikel
123 1.013 Depression presenting before motor manifestation of Parkinson's disease: Impact on motor and cognitive features Klepac, N.
2007
13 S2 p. S30-S31
2 p.
artikel
124 2.205 Design of the A to Z (Agonists to Zelapar) trial: Adding orally disintegrating selegiline to dopamine agonists in patients with Parkinson's disease experiencing complications Isaacson, S.
2007
13 S2 p. S98-
1 p.
artikel
125 2.210 Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa: a randomized, crossover, multicentre study in patients with Parkinson's disease Kaakola, S.
2007
13 S2 p. S100-
1 p.
artikel
126 2.266 Detrimental effect of levodopa on sleep-dependent consolidation of an implicit learning task Wailke, S.
2007
13 S2 p. S116-
1 p.
artikel
127 1.156 Development and evaluation of a dysarthria severity questionnaire for Parkinson's disease (ROMP-speech) Kalf, J.
2007
13 S2 p. S48-
1 p.
artikel
128 1.151 Development and evaluation of a severity scale (DSFS-P) and questionnaire for drooling in Parkinson's isease (ROMP-saliva) Kalf, J.
2007
13 S2 p. S47-
1 p.
artikel
129 1.155 Development and evaluation of a swallowing severity questionnaire for Parkinson's disease (ROMP-swallowing) Kalf, J.
2007
13 S2 p. S48-
1 p.
artikel
130 3.413 Development of a Dutch evidence based guideline for occupational therapy in Parkinson's disease Sturkenboom, I.
2007
13 S2 p. S183-
1 p.
artikel
131 2.404 DHA reduces lipoxidative damage in a A53T mouse model of Parkinson's disease Dalfo, E.
2007
13 S2 p. S128-
1 p.
artikel
132 1.166 Diagnosis of personality structure and cognition in patients with Parkinson's disease Schiavella, M.
2007
13 S2 p. S50-S51
2 p.
artikel
133 3.107 Diagnostic accuracy of SPECT in parkinsonian syndromes: A meta-analysis Vlaar, A.
2007
13 S2 p. S154-
1 p.
artikel
134 2.259 Diagnostic review and medication withdrawal in patients on anti-parkinson therapy: An interim report Newman, E.
2007
13 S2 p. S114-
1 p.
artikel
135 3.109 Diagnostic value of meta-iodobenzyl-guanidine myocardial scintigraphy in the differential diagnosis of senile dementia of the Alzheimer type and Diffuse Lewy Body Disease Versijpt, J.
2007
13 S2 p. S155-
1 p.
artikel
136 3.014 Diagnostic value of meta-iodobenzyl-guanidine myocardial scintigraphy in the differential diagnosis of senile dementia of the Alzheimer type and Diffuse Lewy Body Disease Versijpt, J.
2007
13 S2 p. S149-
1 p.
artikel
137 3.011 Diagnostic value of transcranial duplex scanning and SPECT imaging versus clinical diagnosis (clinical prospective study) Vlaar, A.
2007
13 S2 p. S148-
1 p.
artikel
138 3.112 Diagnostic value of transcranial duplex scanning and SPECT imaging versus clinical diagnosis (clinical prospective study) Vlaar, A.
2007
13 S2 p. S156-
1 p.
artikel
139 1.116 Differential diagnosis and clinical profile in a large population of patients with parkinsonism Munhoz, R.
2007
13 S2 p. S38-
1 p.
artikel
140 2.218 Differential EEG changes for rasagiline, aminoindan and selegiline in the freely moving rat Dimpfel, W.
2007
13 S2 p. S102-
1 p.
artikel
141 3.420 Differential effect of the Parkinson's disease non-motor symptoms on patients' health-related quality of life Naidu, Y.
2007
13 S2 p. S185-
1 p.
artikel
142 3.105 Diffusion tensor tractography of the frontopontine tract in parkinsonian disorders Eriksson, B.
2007
13 S2 p. S154-
1 p.
artikel
143 3.505 Di-nucleotide polymorphism upstream of alpha-synuclein determines susceptibility to Parkinson's disease Fang, Y.
2007
13 S2 p. S188-S189
2 p.
artikel
144 3.210 Discomfort caused by subcutaneous deep brain pulse-generator and lead-extensions Sherif, C.
2007
13 S2 p. S164-
1 p.
artikel
145 3.212 Distinct psychosocial profiles remain stable over time in patients with Parkinson's disease undergoing DBS-STN Kaiser, I.
2007
13 S2 p. S165-
1 p.
artikel
146 2.103 Distribution of LRRK2 in the developing and adult murine brain von Bohlen und Halbach, O.
2007
13 S2 p. S92-S93
2 p.
artikel
147 2.112 DJ-1 regulation of p53 pathway and its impairment by Parkinson's disease-associated mutations Giaime, E.
2007
13 S2 p. S95-
1 p.
artikel
148 2.321 Do chronic non-specific brain insults predispose to incidental Lewy Body Disease? An exploratory study Frigerio, R.
2007
13 S2 p. S127-
1 p.
artikel
149 3.019 Does deep brain stimulation in Parkinson's disease suppress pathological synchronisation? Eusebio, A.
2007
13 S2 p. S151-
1 p.
artikel
150 3.238 Does deep brain stimulation in Parkinson's disease suppress pathological synchronisation? Eusebio, A.
2007
13 S2 p. S172-
1 p.
artikel
151 1.206 Donepezil versus rivastigmine tolerability study in dementia with Lewy bodies and Alzheimer's disease Magierski, R.
2007
13 S2 p. S62-
1 p.
artikel
152 3.016 Dopamine dependent changes in resting-state cortico-cortical synchronisation in mild to moderate Parkinson's disease Stoffers, D.
2007
13 S2 p. S149-S150
2 p.
artikel
153 3.111 Dopamine transporter imaging in Holmes tremor Bogucki, A.
2007
13 S2 p. S156-
1 p.
artikel
154 1.289 Dose adjustment during long-term pramipexole treatment for restless legs syndrome Högl, B.
2007
13 S2 p. S73-
1 p.
artikel
155 2.239 Dose strength equivalence and dose proportionality demonstrated with ropinirole 24-hour prolonged release Vearer, D.
2007
13 S2 p. S108-
1 p.
artikel
156 1.152 Dribbling of saliva in Parkinson's disease: Clinical correlations Lewis, H.
2007
13 S2 p. S47-
1 p.
artikel
157 3.127 Drug-induced Parkinsonism: Clinic–neurosonologic study Baik, J.-S.
2007
13 S2 p. S160-
1 p.
artikel
158 2.268 Drug-related compulsive behaviours in patients with Parkinson's disease Kosma, K.
2007
13 S2 p. S116-
1 p.
artikel
159 1.194 Dual task interference: The effects of verbal cognitive taks on gait initiation in Parkinons's Disease Jenkins, M.
2007
13 S2 p. S58-
1 p.
artikel
160 1.195 Dual task interference: The effects of verbal cognitive tasks on upright postural stability in Parkinson's disease Jenkins, M.
2007
13 S2 p. S58-
1 p.
artikel
161 2.220 Duodenal levodopa infusion for advanced Parkinson's disease: 24-month treatment outcome Mancini, F.
2007
13 S2 p. S103-
1 p.
artikel
162 2.223 Duodopa in advanced Parkinson's disease: First Slovenian experiences Kramberger, M.
2007
13 S2 p. S103-S104
2 p.
artikel
163 1.213 Dysarthria in progressive supranuclear palsy Mallien, G.
2007
13 S2 p. S63-S64
2 p.
artikel
164 3.004 Dystonia Dressler, D.
2007
13 S2 p. S147-
1 p.
artikel
165 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile Grünblatt, E.
2007
13 S2 p. S30-
1 p.
artikel
166 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile Grünblatt, E.
2007
13 S2 p. S33-S34
2 p.
artikel
167 2.272 Early diagnosis of end-of-dose wearing-off signs and symptoms during the treatment of Parkinson's disease (ELPIS) Kkolou, E.
2007
13 S2 p. S117-
1 p.
artikel
168 1.101 Early diagnostic tool of Parkinson's disease in REM sleep behavior disorder: UPSIT and transcranial sonography Shin, H.-Y.
2007
13 S2 p. S34-
1 p.
artikel
169 1.109 Early-onset Parkinson's disease and depression Teive, H.
2007
13 S2 p. S36-
1 p.
artikel
170 Editorial Board 2007
13 S2 p. iii-
1 p.
artikel
171 1.287 Effectiveness of pramipexole in the treatment of RLS: A 12-weeks non-interventional trial in patients with primary restless legs syndrome (RLS) Möller, C.
2007
13 S2 p. S73-
1 p.
artikel
172 2.507 Effect of L-type Ca2 channel antagonist, Isradipine, in the rat model of dyskinesia Schuster, S.
2007
13 S2 p. S144-
1 p.
artikel
173 2.430 Effect of 1-methylxanthine, a possible A2A receptor antagonist on striatopallidal activity Jimenez Botello, L.C.
2007
13 S2 p. S135-
1 p.
artikel
174 2.224 Effect of moderate hepatic impairment and cigarette smoking on the pharmacokinetics of istradefylline Rao, N.
2007
13 S2 p. S104-
1 p.
artikel
175 1.290 Effect of patient age on pramipexole efficacy in the treatment of restless legs syndrome Zesiewicz, T.
2007
13 S2 p. S73-S74
2 p.
artikel
176 2.443 Effect of some naturally occurring antioxidants (vitamins) in the treatment of chronic lead intoxication and on its related impaired dopaminergic neurotransmission in rats Djebli, N.
2007
13 S2 p. S139-
1 p.
artikel
177 2.435 Effect of the SNc lesion on the aminoacid neurotransmitter release and neuronal death in the pedunculopontine nucleus Blanco-Lezcano, L.
2007
13 S2 p. S137-
1 p.
artikel
178 2.255 Effects of apomorphine on neuropsychiatric and cognitive function in patients with Parkinson's disease Postma, A.-G.
2007
13 S2 p. S113-
1 p.
artikel
179 3.227 Effects of bilateral subthalamic nucleus deep brain stimulation on speech intelligibility and movement: A model-based case study Astrom, M.
2007
13 S2 p. S169-
1 p.
artikel
180 2.409 Effects of combined exposure to the pesticide rotenone and the proteasome inhibitor lactacystin on striatal dopamine metabolism in rats Konieczny, J.
2007
13 S2 p. S129-S130
2 p.
artikel
181 2.232 Effects of dopamine agonist pramipexole on sleep disturbances in Parkinson's disease Nodel, M.
2007
13 S2 p. S106-
1 p.
artikel
182 3.235 Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson's disease Eusebio, A.
2007
13 S2 p. S171-
1 p.
artikel
183 1.319 Effects of valproate on dopaminergic system in mice Vamos, E.
2007
13 S2 p. S81-
1 p.
artikel
184 2.215 Efficacy and tolerability of rasagiline in routine clinical practice Kracunova, K.
2007
13 S2 p. S101-
1 p.
artikel
185 2.244 Efficacy of rotigotine transdermal patch as adjunct to levodopa in subgroups of advanced-stage Parkinson's patients LeWitt, P.
2007
13 S2 p. S110-
1 p.
artikel
186 2.412 Efficacy of the NMDA antagonist (BZAD-01) in a rat model of Parkinson's disease (PD): Lesions to the thalamus Truong, L.
2007
13 S2 p. S130-
1 p.
artikel
187 3.425 Efficacy of the Patient Education Program Parkinson (PEPP) A'Campo, L.
2007
13 S2 p. S186-
1 p.
artikel
188 2.226 Electrocardiogram effects of istradefylline: A thorough QTc study in healthy men and women Rao, N.
2007
13 S2 p. S104-S105
2 p.
artikel
189 1.148 Electroencephalographic criteria of epileptic syndrome in patients with parkinsonism Elistratova, T.
2007
13 S2 p. S45-S46
2 p.
artikel
190 2.234 Electropharmacogram of pramipexole in the freely moving rat Dimpfel, W.
2007
13 S2 p. S107-
1 p.
artikel
191 2.406 Enhanced GABA release in the medial globus pallidus in a rat model of L-DOPA-induced dyskinesia Tomiyama, M.
2007
13 S2 p. S129-
1 p.
artikel
192 3.201 Enhanced survival and function of neural stem cells derived dopaminergic neurons under surveillance of olfactory ensheathing cells in parkinsonian rats Shukla, S.
2007
13 S2 p. S161-
1 p.
artikel
193 3.211 Entopeduncular deep brain stimulation induces a triphasic response in entopeduncular neurons in a genetic hamster model of generalised paroxysmal dystonia Meissner, W.
2007
13 S2 p. S164-
1 p.
artikel
194 3.003 Epidemiology Breteler, M.
2007
13 S2 p. S147-
1 p.
artikel
195 2.287 Escitalopram induced psychotic episode in Parkinson's disease: A case report Zarubova, K.
2007
13 S2 p. S121-
1 p.
artikel
196 3.409 Evaluation of a Multidisciplinary Assessment Center for patients with Parkinson's disease (PD) van der Marck, M.
2007
13 S2 p. S182-
1 p.
artikel
197 2.225 Evaluation of the pharmacokinetic interaction of istradefylline and ketoconazole Rao, N.
2007
13 S2 p. S104-
1 p.
artikel
198 1.190 Everyday life consequences of Parkinson's disease: Community participation and integration Sgaramella, T.M.
2007
13 S2 p. S57-
1 p.
artikel
199 3.119 Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11 C-raclopride PET study Politis, M.
2007
13 S2 p. S158-
1 p.
artikel
200 1.016 Excessive daytime sleepiness and fatigue are not associated features of Parkinson's disease Havlikova, E.
2007
13 S2 p. S31-
1 p.
artikel
201 1.135 Excessive daytime sleepiness and fatigue are not associated features of Parkinson's disease Havlikova, E.
2007
13 S2 p. S42-
1 p.
artikel
202 3.230 Exercise performance in Parkinson's disease before and 3 months after DBS-STN operation Jørgensen, H.U.
2007
13 S2 p. S170-
1 p.
artikel
203 1.255 Experience of up to ten years treatment with albumin-diluted botulinum toxin type A Mohammadi, B.
2007
13 S2 p. S66-
1 p.
artikel
204 3.209 Extension wire tethering: A late post operative complication for deep brain stimulation Moore, H.J.
2007
13 S2 p. S164-
1 p.
artikel
205 3.400 External cueing and activity in the Parkinsonian brain: Development of a motor paradigm Buma, F.
2007
13 S2 p. S180-
1 p.
artikel
206 2.101 Familial genes in sporadic Parkinson's disease Ross, O.
2007
13 S2 p. S92-
1 p.
artikel
207 2.011 Familial genes in sporadic Parkinson's disease Ross, O.
2007
13 S2 p. S88-
1 p.
artikel
208 3.114 FDG-PET findings of Parkinson's disease with mild cognitive impairment Lee, M.-S.
2007
13 S2 p. S156-S157
2 p.
artikel
209 3.206 First experiences with a decision tool to support appropriate referral for Deep Brain Stimulation in patients with Parkinson's disease Herzog, J.
2007
13 S2 p. S163-
1 p.
artikel
210 1.259 Frontalis, corrugator and procerus dystonia: A blepharospasm variant? Fabiani, G.
2007
13 S2 p. S67-
1 p.
artikel
211 1.311 Frontotemporal dementia caused by neurodegeneration with brain iron accumulation Frizell Santillo, A.
2007
13 S2 p. S79-S80
2 p.
artikel
212 3.101 Functional connectivity in Parkinson's disease related dementia: A MEG study Bosboom, J.L.
2007
13 S2 p. S152-S153
2 p.
artikel
213 1.269 Functional MRI in two sisters with orthostatic tremor Malm, S.
2007
13 S2 p. S69-
1 p.
artikel
214 3.305 Gait abnormalities in Parkinson's disease detected by free ambulatory monitoring Siclari, F.
2007
13 S2 p. S176-
1 p.
artikel
215 3.304 Gait disorders and increase of the step variability for cerebrovascular diseases: Diagnostics using the computer hardware–software complex “Dorozhka” Pokhabov, D.
2007
13 S2 p. S176-
1 p.
artikel
216 1.324 Genetic background in Japanese patients with sporadic spinocerebellar degeneration Adachi, Y.
2007
13 S2 p. S83-
1 p.
artikel
217 2.116 Genetic characterization of ATP13A2 in Parkinson's disease Vilarino-Guell, C.
2007
13 S2 p. S96-
1 p.
artikel
218 1.503 Genetics, plasticity and dyskinesia in PD Linazasoro, G.
2007
13 S2 p. S84-
1 p.
artikel
219 1.281 Glutathione-S-transferase P1 polymorphism and risk for essential tremor Navarro, H. Alonso
2007
13 S2 p. S71-
1 p.
artikel
220 2.414 Glutathione system in rotenone induced Parkinson disease model: Improvement by co-treatment of centrophenoxine Nehru, B.
2007
13 S2 p. S131-
1 p.
artikel
221 3.414 Guidelines for speech–language therapy in Parkinson's disease Kalf, J.
2007
13 S2 p. S183-S184
2 p.
artikel
222 1.299 Head-to-head comparison of transdermal lisuride and oral ropinirole in Restless Legs Syndrome: Results from the first placebo- and active-controlled, double-blind, randomized, 12-week efficacy trial Benes, H.
2007
13 S2 p. S76-
1 p.
artikel
223 1.279 Hereditary geniospasm in a Turkish family Turkmen, C.
2007
13 S2 p. S71-
1 p.
artikel
224 1.312 Heterozygous carriers for Wilson's disease – magnetic spectroscopy changes in the brain Tarnacka, B.
2007
13 S2 p. S80-
1 p.
artikel
225 2.281 High risk factors for valvular heart disease from dopamine agonists in Parkinson's disease Oeda, T.
2007
13 S2 p. S120-
1 p.
artikel
226 1.277 Holmes' tremor and treatment with pramipexole Oztekin, N.
2007
13 S2 p. S70-
1 p.
artikel
227 1.102 Homocysteine and asymmetric dimethylarginine (ADMA) in the plasma of patients with Parkinson's disease Dorszewska, J.
2007
13 S2 p. S34-
1 p.
artikel
228 3.221 Hormonal dysregulation contributes to weight gain after DBS STN in Parkinson's disease Novakova, L.
2007
13 S2 p. S167-
1 p.
artikel
229 3.020 How the study design influences perceived personality traits changes in Parkinson's disease (PD) after subthalamic deep brain stimulation (DBS-STN) Gronchi-Perrin, A.
2007
13 S2 p. S151-
1 p.
artikel
230 3.222 How the study design influences perceived personality traits changes in Parkinson's disease (PD) after subthalamic deep brain stimulation (DBS-STN) Gronchi-Perrin, A.
2007
13 S2 p. S167-S168
2 p.
artikel
231 3.315 How to assess easily the quadricipital strength for the management of rising and walking difficulties in Parkinson's disease? Vanderheyden, J.-E.
2007
13 S2 p. S179-S180
2 p.
artikel
232 1.301 Hydrocephalus and Parkinsonian disorders: difficulties in differential diagnosis Gontu, V.
2007
13 S2 p. S77-
1 p.
artikel
233 2.316 6-Hydroxydopamine nigrostriatal lesion modulates alpha-synuclein expression in different rat brain regions Perovic, M.
2007
13 S2 p. S125-S126
2 p.
artikel
234 1.304 Hyperactivity and attention deficit precede the development of Parkinson's disease symptoms Gerlach, M.
2007
13 S2 p. S77-S78
2 p.
artikel
235 2.286 Hypersexuality in a patient with Parkinson's disease after use of pramipexole: Case report Munhoz, R.
2007
13 S2 p. S121-
1 p.
artikel
236 1.113 Hyposmia, cognitive dysfunction and the future risk of Parkinson's disease: A five-year prospective study Ponsen, M.
2007
13 S2 p. S37-
1 p.
artikel
237 2.314 Identification of modifiers of alpha-synuclein inclusion in a C. elegans model by genome-wide RNAi van Ham, T.
2007
13 S2 p. S125-
1 p.
artikel
238 2.019 Identification of modifiers of alpha-synuclein inclusion in a C. elegans model by genome-wide RNAi van Ham, T.
2007
13 S2 p. S90-S91
2 p.
artikel
239 2.315 Identification of potent small molecule inhibitors of alpha-synuclein aggregation in cell culture and by in vitro screening Snow, A.
2007
13 S2 p. S125-
1 p.
artikel
240 1.003 Imaging techniques Leenders, K.L.
2007
13 S2 p. S29-
1 p.
artikel
241 3.203 Immortalized mesencephalic progenitor cells – cellular and molecular characterization in vitro dos Santos Nobre, A.
2007
13 S2 p. S162-
1 p.
artikel
242 3.216 Impact of chronic deep brain stimulation of the subthalamic nucleus in advanced Parkinson's disease Cheon, S.-M.
2007
13 S2 p. S166-
1 p.
artikel
243 3.506 Impact of sleep problems on health-related quality of life of Parkinson's disease patients and their caregivers Martinez-Martin, P.
2007
13 S2 p. S189-
1 p.
artikel
244 1.111 Impaired odour recognition memory in Parkinson's disease Boesveldt, S.
2007
13 S2 p. S36-
1 p.
artikel
245 2.212 Improved adherence to levodopa/carbidopa/entacapone (Stalevo®) or levodopa/carbidopa and entacapone as separate tablets reduces medical care utilization and costs among Parkinson's disease patients Delea, T.
2007
13 S2 p. S100-S101
2 p.
artikel
246 2.213 Improved antiparkinsonian effects during the night with levodopa/dopa decarboxylase inhibitor and entacapone compared with levodopa/dopa decarboxylase inhibitor in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off Nissinen, H.
2007
13 S2 p. S101-
1 p.
artikel
247 3.416 Improved sensitivity for functional assessment of Parkinson's disease rehabilitation using the Mobility, Occupational & Vocational Examination (MOVE) test Jaffe, M.
2007
13 S2 p. S184-
1 p.
artikel
248 1.291 Improvement in activities of daily living among patients receiving pramipexole for restless legs syndrome (RLS) Lainey, E.
2007
13 S2 p. S74-
1 p.
artikel
249 2.248 Improvement of nocturnal symptoms in patients with idiopathic Parkinson's disease using rotigotine transdermal Trenkwalder, C.
2007
13 S2 p. S111-
1 p.
artikel
250 1.199 Increased reaction time predicts deficit of explicit visual learning in the early stages of Parkinson's disease Ghilardi, M.F.
2007
13 S2 p. S59-S60
2 p.
artikel
251 1.172 Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson's disease Arabia, G.
2007
13 S2 p. S52-
1 p.
artikel
252 2.309 Induced folding of recombinant alpha-synuclein: Role of chemical chaperones Veldhuis, G.
2007
13 S2 p. S124-
1 p.
artikel
253 2.436 Induction of heme oxygenase-1 by proteasome inhibition is involved in the protection of dopaminergic neurons: implication of ubiquitin-proteasome degradation Yamamoto, N.
2007
13 S2 p. S137-
1 p.
artikel
254 1.138 Insomnia in patients with Parkinson's disease in Armenia (a pilot study) Khachatryan, S.
2007
13 S2 p. S43-
1 p.
artikel
255 2.221 Intestinal levodopa infusion in advanced Parkinson's disease Baumhackl, U.
2007
13 S2 p. S103-
1 p.
artikel
256 3.313 Investigating the content of a cueing therapy program: The RESCUE trial Lim, I.
2007
13 S2 p. S179-
1 p.
artikel
257 3.013 Investigation of the role of expectation in the mechanism of the placebo effect in Parkinson's disease using high-resolution positron emission tomography (PET) with [11C] raclopride Lidstone, S.
2007
13 S2 p. S149-
1 p.
artikel
258 3.118 Investigation of the role of expectation in the mechanism of the placebo effect in Parkinson's disease using high-resolution positron emission tomography (PET) with [11C] raclopride Lidstone, S.
2007
13 S2 p. S158-
1 p.
artikel
259 2.249 Investigation on the prevalence of dyskinesia following the switch from pulsatile rotigotine or L-DOPA to continuous rotigotine Scheller, D.
2007
13 S2 p. S111-
1 p.
artikel
260 3.131 In vivo imaging of the human cerebral cannabinoid-type 1 receptor in Huntington's disease Vandenberghe, W.
2007
13 S2 p. S161-
1 p.
artikel
261 2.431 In vivo neurochemical effects of the voltage dependent NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats Sarre, S.
2007
13 S2 p. S135-S136
2 p.
artikel
262 3.130 Ischemic brain lesion and plasma homocysteine in Parkinson's disease Maeda, T.
2007
13 S2 p. S161-
1 p.
artikel
263 3.IS.1. Continuous delivery of ropinirole: Improving the management of Parkinson's disease (GlaxoSmithKline) Schapira, Anthony
2007
13 S2 p. S190-
1 p.
artikel
264 1.IS.4.2 Continuous dopaminergic stimulation (CDS) in Parkinson's disease (PD) achieved by s.c. infusion of lisuride Stocchi, F.
2007
13 S2 p. S86-
1 p.
artikel
265 1.IS.4. Continuous dopaminergic stimulation (CDS) – new insights (Axxonis Pharma AG/formerly NeuroBiotec) Franz Riederer, Peter
2007
13 S2 p. S86-
1 p.
artikel
266 2.IS.3.3 Deep brain stimulation or Duodopa: Choosing the right therapy for individual patients Volkmann, J.
2007
13 S2 p. S146-
1 p.
artikel
267 2.IS.2.3 Depression and Parkinson's disease – The dopaminergic link Leentjens, A.F.G.
2007
13 S2 p. S145-S146
2 p.
artikel
268 2.IS.2.1 Dopamine agonists in controlling motor symptoms – clinical relevance of trials Emre, M.
2007
13 S2 p. S145-
1 p.
artikel
269 1.IS.4.3 Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) Ebersbach, G.
2007
13 S2 p. S86-
1 p.
artikel
270 1.282 Is functional decline in essential tremor and Parkinson's disease alike? Frisina, P.
2007
13 S2 p. S71-S72
2 p.
artikel
271 2.264 Is genetic polymorphism of angiotensin-converting enzyme associated with the development of L-Dopa induced adverse effects? Meco, G.
2007
13 S2 p. S115-
1 p.
artikel
272 2.410 Is H5N1 influenza virus a novel etiological agent in the development of post-encephalitic parkinsonism? Smeyne, R.
2007
13 S2 p. S130-
1 p.
artikel
273 3.IS.4.3 How to start in your clinic? Implementation and practical guidelines Munneke, M.
2007
13 S2 p. S191-
1 p.
artikel
274 3.IS.4.2 Multidisciplinary care for PD: Does it really work? Guttman, M.
2007
13 S2 p. S191-
1 p.
artikel
275 3.IS.4.1 Multidisciplinary care for PD: Who should be part of the team? Iansek, B.
2007
13 S2 p. S191-
1 p.
artikel
276 1.IS.4.1 New diagnostic and therapeutic aspects of RLS Kohnen, R.
2007
13 S2 p. S86-
1 p.
artikel
277 1.IS.1. New paradigm shifts in deep brain stimulation (Medtronic) Volkmann, Jens
2007
13 S2 p. S85-
1 p.
artikel
278 2.IS.1. New treatment possibilities with oral Levodopa (Novartis Pharma AG/Orion Corporation) Schapira, Anthony
2007
13 S2 p. S144-S145
2 p.
artikel
279 1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia Pharmaceuticals Ltd.) van Laar, Teus
2007
13 S2 p. S86-
1 p.
artikel
280 3.IS.3.3 Parkinson's treatment: The patient's view Grosset, D.
2007
13 S2 p. S190-S191
2 p.
artikel
281 3.IS.3.1 Patch technology as a novel option for continuous drug delivery Stocchi, F.
2007
13 S2 p. S190-
1 p.
artikel
282 1.305 Is psychopathology part of the phenotypic spectrum of myoclonus–dystonia? A study of a large Dutch M-D family Foncke, E.
2007
13 S2 p. S78-
1 p.
artikel
283 1.020 Is psychopathology part of the phenotypic spectrum of Myoclonus–Dystonia? A study of a large Dutch M-D family Foncke, E.
2007
13 S2 p. S32-
1 p.
artikel
284 1.IS.2. Rasagiline – optimising treatment outcomes throughout the progression of PD (Teva/Lundbeck) Lees, Andrew
2007
13 S2 p. S85-
1 p.
artikel
285 2.IS.2.2 Revised UPDRS-assessment of the broad range of symptoms in Parkinson's disease Sampaio, C.
2007
13 S2 p. S145-
1 p.
artikel
286 1.154 Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients? Melo, A.
2007
13 S2 p. S47-S48
2 p.
artikel
287 2.301 Is the Braak's staging really useful? A correlation analysis of neurodegeneration markers in cerebrospinal fluid and motor impairment in Parkinson disease Vranova, H.
2007
13 S2 p. S121-S122
2 p.
artikel
288 3.IS.2. The changing face of Parkinson's disease: From Motor symptoms to cognition to neuroprotection (Merck Serono International) Emre, Murat
2007
13 S2 p. S190-
1 p.
artikel
289 2.IS.3.2 The Dutch experience with Duodopa in the endstages of Parkinson's disease van Laar, T.
2007
13 S2 p. S146-
1 p.
artikel
290 2.IS.3.1 The importance of steady state blood dopa levels in reducing motor fluctuations Lees, A.
2007
13 S2 p. S146-
1 p.
artikel
291 3.IS.3.2 Treating Parkinson's symptoms 24 hours – Day and night Chaudhuri, K.R.
2007
13 S2 p. S190-
1 p.
artikel
292 3.110 Juvenile Parkinson's disease presenting as essential tremor Dalla Libera, A.
2007
13 S2 p. S155-
1 p.
artikel
293 1.123 Knowledge about non motor symptoms in Parkinson's disease patients and their close relatives Vivanco Hidalgo, R.M.
2007
13 S2 p. S39-
1 p.
artikel
294 2.118 Lack of association between genetic polymorphism of angiotensin-converting enzyme and Parkinson's disease Meco, G.
2007
13 S2 p. S96-S97
2 p.
artikel
295 1.217 Late post-poliomyelitis syndrome with secondary parkinsonism Ilinca, A.
2007
13 S2 p. S65-
1 p.
artikel
296 1.315 Late post-poliomyelitis syndrome with secondary parkinsonism Macovei, M.
2007
13 S2 p. S80-
1 p.
artikel
297 2.505 L-DOPA induces microvascular changes in the basal ganglia through the D1 receptor in a rat model of Parkinson's disease Ohlin, E.
2007
13 S2 p. S143-S144
2 p.
artikel
298 2.275 L-Dopa plasma levels variability in Parkinson's disease Albani, G.
2007
13 S2 p. S118-
1 p.
artikel
299 2.503 Lentivirally-delivered GRK6 for decreasing severity of levodopa-induced dyskinesia Bezard, E.
2007
13 S2 p. S143-
1 p.
artikel
300 2.204 Levodopa ingestion and metabolism in patients with idiopathic Parkinson's disease Adams, F.
2007
13 S2 p. S98-
1 p.
artikel
301 2.303 Lipoxidized, nitrated and phosphorylated alpha-synuclein in amygdala-predominant Lewy body disease Martínez, A.
2007
13 S2 p. S122-
1 p.
artikel
302 2.284 Lisuride is devoid of 5-HT2B receptor agonism and there are no case reports of cardiac valvulopathy Latté, K.P.
2007
13 S2 p. S120-S121
2 p.
artikel
303 2.252 Lisuride long term s.c. infusion in advanced Parkinson's disease patients unresponsive to oral treatments Stocchi, F.
2007
13 S2 p. S112-
1 p.
artikel
304 3.241 Localization of spontaneous thalamic local field potential activity recorded during stereotactic functional neurosurgery Kempf, F.
2007
13 S2 p. S173-
1 p.
artikel
305 1.205 Longitudinal neuropsychometric assessment in patients with Parkinson's disease Dementia: Effect of rivastigmine Kassubek, J.
2007
13 S2 p. S61-
1 p.
artikel
306 2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease Anand, R.
2007
13 S2 p. S99-S100
2 p.
artikel
307 3.122 Long term effects of implants of human retinal pigment epithelial cells on gelatin microcarriers (hRPE-GM) (Spheramine®) in MPTP-treated primates: Behavior and PET imaging Doudet, D.
2007
13 S2 p. S159-
1 p.
artikel
308 1.254 Long-term follow-up of cervical dystonia patients treated with Botulinum toxin A Kollewe, K.
2007
13 S2 p. S66-
1 p.
artikel
309 2.245 Long-term safety and efficacy of rotigotine transdermal patch in early-stage Parkinson's disease Watts, R.
2007
13 S2 p. S110-
1 p.
artikel
310 2.253 Long term use of apomorphine in Parkinson's disease Tagaris, G.
2007
13 S2 p. S112-
1 p.
artikel
311 1.018 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study Caretti, V.
2007
13 S2 p. S32-
1 p.
artikel
312 1.270 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study Caretti, V.
2007
13 S2 p. S70-
1 p.
artikel
313 2.402 Low-dose pesticide exposure and early stages of Parkinsonism in a rat model Vanbesien-Mailliot, C.
2007
13 S2 p. S128-
1 p.
artikel
314 3.243 Low-frequency repetitive transcranial magnetic stimulation (rTMS) reduces levodopa induced diphasic dyskinesias in Parkinson's disease (PD): A case report Filipovic, S.
2007
13 S2 p. S173-S174
2 p.
artikel
315 2.231 Maintained pramipexole monotherapy treatment results in significantly lower dyskinesia rates in early Parkinson's disease: A result of the CALM-PD study after 4 years Corbin, A.
2007
13 S2 p. S106-
1 p.
artikel
316 1.318 Malignant neuroleptic syndrome in a case of acute extrapontine myelinolysis Stellmann, J.-P.
2007
13 S2 p. S81-
1 p.
artikel
317 3.308 Measuring gait and gait-related activities in Parkinson's patients own home environment: A reliability, responsiveness and feasibility study Lim, I.
2007
13 S2 p. S177-
1 p.
artikel
318 2.426 Mechanism of degradation of Bad protein by the green tea polyphenol (−)-epigallocatechin-3-gallate: Implication for neuroprotection Kalfon, L.
2007
13 S2 p. S134-
1 p.
artikel
319 2.203 Medicinal plants as (new) sources for antiparkinsonian therapy Latté, K.P.
2007
13 S2 p. S98-
1 p.
artikel
320 2.311 Microglial NADPH oxidase and macrophage antigen-1 receptor are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein Zhang, W.
2007
13 S2 p. S124-
1 p.
artikel
321 2.267 Migraine attacks after dopaminergetic drugs holidays in Parkinson's disease (PD) Kountouris, D.
2007
13 S2 p. S116-
1 p.
artikel
322 1.185 Mild cognitive impairment in Parkinson's disease Petrovic, M.
2007
13 S2 p. S55-
1 p.
artikel
323 1.117 Mistakes at the beginning of Parkinson disease: Report of clinical cases Pavlic, G.
2007
13 S2 p. S38-
1 p.
artikel
324 2.422 Mitochondrial ultrastructural abnormalities and disrupted neurotransmitter-storage bodies in Parkinson's disease Issidorides, M.R.
2007
13 S2 p. S133-
1 p.
artikel
325 1.504 Modifiable and non-modifiable, intrinsic and extrinsic risk factors for dyskenesia in Parkinson's disease Sharma, J.
2007
13 S2 p. S84-
1 p.
artikel
326 2.276 Molecular mechanism of L-Dopa induced dyskinesia in Parkinson's disease Subhani, F.U.-H.
2007
13 S2 p. S118-S119
2 p.
artikel
327 2.015 Molecular mechanism of L-Dopa induced dyskinesia in Parkinson's disease Subhani, F.U.-H.
2007
13 S2 p. S89-S90
2 p.
artikel
328 2.417 Monitoring tyrosine hydroxylase activity and effects of drugs in organotypic mesencephalic cultures Gramsbergen, J.B.
2007
13 S2 p. S132-
1 p.
artikel
329 2.504 Monoamine neurotransmission in the rat model of L-DOPA-induced dyskinesia Andersson, D.
2007
13 S2 p. S143-
1 p.
artikel
330 1.207 Mortality in a community based cohort of Parkinson's disease patients with and without dementia in a rural area of North Wales in the United Kingdom Hobson, P.
2007
13 S2 p. S62-
1 p.
artikel
331 2.403 MPTP-induced parkinsonian syndrome in Senescence Accelerated Mice (SAM) Stvolinsky, S.
2007
13 S2 p. S128-
1 p.
artikel
332 3.102 MRI in Parkinson's disease identifies shape, but not volume, changes in the thalamus McKeown, M.
2007
13 S2 p. S153-
1 p.
artikel
333 3.121 Multitracer positron emission tomographic study of longitudinal progression of Parkinson's disease: implications for pathogenesis Ramachandiran, N.
2007
13 S2 p. S159-
1 p.
artikel
334 3.012 Multitracer positron emission tomographic study of longitudinal progression of Parkinson's disease: implications for pathogenesis Ramachandiran, N.
2007
13 S2 p. S148-
1 p.
artikel
335 3.248 Neurogenesis in the adult mammalian substantia nigra Janson Lang, A.M.
2007
13 S2 p. S175-
1 p.
artikel
336 2.439 Neuronal recovery in a rodent model of PD following environmental enrichment Van Kampen, J.
2007
13 S2 p. S138-
1 p.
artikel
337 2.312 Neuropathological substrate of parkinsonism: A clinicopathological study of a large general autopsy series Tenenholz Grinberg, L.
2007
13 S2 p. S124-
1 p.
artikel
338 2.018 Neuropathology of conditional alpha-synuclein transgenic mouse models of Parkinson's disease Nuber, S.
2007
13 S2 p. S90-
1 p.
artikel
339 2.304 Neuropathology of conditional alpha-synuclein transgenic mouse models of Parkinson's disease Nuber, S.
2007
13 S2 p. S122-
1 p.
artikel
340 2.440 Neuroprotection by L-DOPA against chronic MPTP in C57/Bl6 mice Liu, S.
2007
13 S2 p. S138-
1 p.
artikel
341 2.449 Neuroprotection by rotigotine requires activation of dopamine D2 receptor and Akt/glycogen synthase kinase-3beta Scheller, D.
2007
13 S2 p. S141-
1 p.
artikel
342 3.224 Neuropsychological effects of bilateral STN DBS in advanced Parkinson's disease Borgohain, R.
2007
13 S2 p. S168-
1 p.
artikel
343 3.225 Neuropsychological outcome of bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease Polito, C.
2007
13 S2 p. S168-
1 p.
artikel
344 3.005 Neurosurgical interventions Alesch, F.
2007
13 S2 p. S148-
1 p.
artikel
345 1.119 New altered motion types in jerking, sympathetic, spasmlike movement disorders Echebarria, S.G.
2007
13 S2 p. S38-
1 p.
artikel
346 2.441 Nicotine provides protective effects in dopaminergic neurons via the nicotinic receptors Takeuchi, H.
2007
13 S2 p. S138-
1 p.
artikel
347 1.212 NINDS-SPSP criteria and clinical phenotype of progressive supranuclear palsy Shibayama, H.
2007
13 S2 p. S63-
1 p.
artikel
348 3.214 Nine-year follow up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease Raglione, L.M.
2007
13 S2 p. S165-
1 p.
artikel
349 2.254 Non-interventional study on subcutaneous apomorphine in the treatment of ON/OFF fluctuations in patients with Parkinson's disease – an interim analysis Sixel-Doering, F.
2007
13 S2 p. S113-
1 p.
artikel
350 1.125 Non-motor symptoms clustering in Parkinson's disease: The PRIAMO study Colosimo, C.
2007
13 S2 p. S40-
1 p.
artikel
351 1.126 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results form the international PD non-motor symptoms scale study Naidu, Y.
2007
13 S2 p. S40-
1 p.
artikel
352 1.014 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results from the international PD non-motor symptoms scale study Naidu, Y.
2007
13 S2 p. S31-
1 p.
artikel
353 1.129 Noradrenaline in the olfactory bulb of Parkinson patients Timmermans-Huisman, E.
2007
13 S2 p. S41-
1 p.
artikel
354 1.307 Objective ear click of middle-ear myoclonus induced by a welding flux into ear canal Ha, C.-K.
2007
13 S2 p. S78-
1 p.
artikel
355 1.146 Observational study of musculoskeletal problems affecting hand function in Parkinson's disease. Green, S.
2007
13 S2 p. S45-
1 p.
artikel
356 3.205 Observation of involuntary movements through clinical effects of surgical treatments Yokochi, F.
2007
13 S2 p. S163-
1 p.
artikel
357 3.310 Obstacle avoidance while walking on a motorized treadmill provokes freezing of gait Snijders, A.
2007
13 S2 p. S178-
1 p.
artikel
358 1.004 Ocular movement disorders Daroff, B.
2007
13 S2 p. S29-
1 p.
artikel
359 1.112 Olfactory dysfunction in Parkinson's disease: Is extended testing useful to discriminate between patients and controls? Boesveldt, S.
2007
13 S2 p. S37-
1 p.
artikel
360 2.274 Onset age or age for initial L-dopa treatment: Which is a more important risk factor for L-DOPA-induced dyskinesia in Parkinson's disease? Kimura, T.
2007
13 S2 p. S118-
1 p.
artikel
361 3.418 Osteoporosis in Parkinson's disease: Comparative study with age-matched normal population Chung, S.-J.
2007
13 S2 p. S184-S185
2 p.
artikel
362 3.415 Overview of current speech–language therapy for patients with Parkinson's disease in the Netherlands Kalf, J.
2007
13 S2 p. S184-
1 p.
artikel
363 2.413 Oxidative stress in rotenone model of Parkinson's disease: Amelioration by co-treatment of centrophenoxine Verma, R.
2007
13 S2 p. S131-
1 p.
artikel
364 1.134 Pain and Parkinson's disease: A case-control Italian multicenter study Michele, T.
2007
13 S2 p. S42-
1 p.
artikel
365 2.307 p25a induces alpha-synuclein dependent cell death in a cellular model for neurodegenerative disorders Petersen, C.
2007
13 S2 p. S123-
1 p.
artikel
366 1.133 Pain in Parkinson's disease Beiske, A.
2007
13 S2 p. S42-
1 p.
artikel
367 2.278 Palilalia as a symptom of levodopa-induced oromotor hyperkinesia in Parkinson's disease Shin, H.-Y.
2007
13 S2 p. S119-
1 p.
artikel
368 1.210 P25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy Christine Song, Y.J.
2007
13 S2 p. S63-
1 p.
artikel
369 3.504 Parkin, PINK1 and DJ-1 mutations in Dutch patients with early-onset parkinsonism Gama Reis Macedo, M.
2007
13 S2 p. S188-
1 p.
artikel
370 2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset Ghione, I.
2007
13 S2 p. S97-
1 p.
artikel
371 1.211 Parkinsonism and dropped-head: Dystonia, myopathy, or both? McKeon, A.
2007
13 S2 p. S63-
1 p.
artikel
372 1.165 Parkinson's disease and dysmotivation for exercise Jaffe, L.
2007
13 S2 p. S50-
1 p.
artikel
373 1.214 Parkinson's disease in Jamaica Josephs, K.
2007
13 S2 p. S64-
1 p.
artikel
374 3.220 Parkinson's disease patients become overweight after STN DBS Bannier, S.
2007
13 S2 p. S167-
1 p.
artikel
375 3.404 ParkNet: A multifaceted strategy to implement practice guidelines for physiotherapy in Parkinson's disease Munneke, M.
2007
13 S2 p. S181-
1 p.
artikel
376 3.405 ParkNet implementation: Evaluation of health benefits Keus, S.H.J.
2007
13 S2 p. S181-
1 p.
artikel
377 2.108 PARK2 screening unmasks never smokers in PD population of North West India Anand, A.
2007
13 S2 p. S94-
1 p.
artikel
378 1.505 Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: Role of pre- and postsynaptic mechanisms Linazasoro, G.
2007
13 S2 p. S85-
1 p.
artikel
379 1.288 Patient-rated efficacy of pramipexole for restless legs syndrome: Results from three double-blind trials Albrecht, S.
2007
13 S2 p. S73-
1 p.
artikel
380 2.302 Pattern of alpha-synuclein and phosphorylated tau pathology in the olfactory bulb, brainstem and limbic regions in aged individuals van de Berg, W.
2007
13 S2 p. S122-
1 p.
artikel
381 2.017 Pattern of α-synuclein and phosphorylated tau pathology in the olfactory bulb, brainstem and limbic regions in aged individuals van de Berg, W.
2007
13 S2 p. S90-
1 p.
artikel
382 2.002 PD: Autonomic dysfunction Reichmann, H.
2007
13 S2 p. S87-
1 p.
artikel
383 2.001 PD: Cognition and dementia Aarsland, D.
2007
13 S2 p. S87-
1 p.
artikel
384 3.426 PDCreativity.org: A web-based resource for improving the quality of life of people with Parkinson's disease Stone, S.
2007
13 S2 p. S186-S187
2 p.
artikel
385 1.002 PD: Dysregulation syndrome Burn, D.J.
2007
13 S2 p. S29-
1 p.
artikel
386 4.001 PD: Gait and balance disorders Giladi, N.
2007
13 S2 p. S192-
1 p.
artikel
387 3.002 PD: Genetics Riess, O.
2007
13 S2 p. S147-
1 p.
artikel
388 1.001 PD: Motor and non-motor fluctuations van Laar, T.
2007
13 S2 p. S29-
1 p.
artikel
389 3.001 PD: Psychosis and depression Goldman, J.
2007
13 S2 p. S147-
1 p.
artikel
390 4.002 PD: Sleep disorders Högl, B.
2007
13 S2 p. S192-
1 p.
artikel
391 2.228 Pergolide in the treatment of Parkinson's disease: Good management or harmful drug? Bares, M.
2007
13 S2 p. S105-
1 p.
artikel
392 2.012 Perry's syndrome is a unique TDP-43 proteinopathy Wider, C.
2007
13 S2 p. S88-S89
2 p.
artikel
393 2.115 Perry's syndrome is a unique TDP-43 proteinopathy Wider, C.
2007
13 S2 p. S96-
1 p.
artikel
394 1.170 Personality tendency and depressed mood among patients with Parkinson's disease Hasegawa, K.
2007
13 S2 p. S52-
1 p.
artikel
395 1.216 Phenotypic characterization of parkinsonism in seven patients with Gaucher Disease Sathe, S.
2007
13 S2 p. S64-
1 p.
artikel
396 2.319 Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's Disease, and in Parkinson's disease and related alpha-synucleinopathies Muntané, G.
2007
13 S2 p. S126-
1 p.
artikel
397 1.161 Plasma homocysteine concentration and peripheral neuropathy in Parkinson's disease patients: A pilot study Nevrly, M.
2007
13 S2 p. S49-
1 p.
artikel
398 2.269 Plasma homocysteine levels in idiopathic Parkinson's disease: Role of idiopathic Parkinson's disease and levodopa treatment Ha, S.-W.
2007
13 S2 p. S116-
1 p.
artikel
399 3.244 Polyphasic MEPs in myoclonus dystonia: A TMS study van der Salm, S.
2007
13 S2 p. S174-
1 p.
artikel
400 2.451 Possible antioxidant mechanisms of cyclooxygenase inhibitors against 3-nitropropionic acid induced neurotoxicity in rats Kumar, A.
2007
13 S2 p. S141-
1 p.
artikel
401 2.251 Possible neuroprotective properties of the dopamine agonist lisuride Horowski, R.
2007
13 S2 p. S112-
1 p.
artikel
402 1.268 Postural tremor in Parkinson's disease (PD): Types of accelerometer traces Boika, A.
2007
13 S2 p. S69-
1 p.
artikel
403 3.303 Posturographic correlates of postural instability in patients with idiopathic Parkinson's disease on and off medication Younis, G.
2007
13 S2 p. S176-
1 p.
artikel
404 2.230 Pramipexole monotherapy in the treatment of early Parkinson's disease: Results of a 3 year follow up of a randomized controlled study Oztekin, N.
2007
13 S2 p. S106-
1 p.
artikel
405 3.419 Predictors of functional ability and quality of life in Parkinson's disease Muslimovic, D.
2007
13 S2 p. S185-
1 p.
artikel
406 3.507 Predictors of health-related quality of life in patients with Parkinson's disease Martinez-Martin, P.
2007
13 S2 p. S189-
1 p.
artikel
407 1.121 Predictors of Parkinson's disease progression Ritter, S.
2007
13 S2 p. S39-
1 p.
artikel
408 1.175 Prevalence of depression in patients with Parkinson's disease in Armenia (a pilot study) Tavadyan, Z.
2007
13 S2 p. S53-
1 p.
artikel
409 1.124 Prevalence, pattern, and severity of non-motor symptoms in drug-naïve early Parkinson disease patients: Non-Motor Symptom assessment Scale (NMSS) for Parkinson Disease Kim, H.J.
2007
13 S2 p. S39-
1 p.
artikel
410 1.253 Primary lingual dystonia induced by speaking and improvement with singing: A similarity with stuttering Ozen, B.
2007
13 S2 p. S66-
1 p.
artikel
411 1.325 PRNP and APOE genetic polymorphisms in a Polish population of amyotrophic lateral sclerosis patients Flirski, M.
2007
13 S2 p. S83-
1 p.
artikel
412 1.316 Prochlorperazine induced acute parkinsonism in a patient with HIV: A case report Bernbaum, M.
2007
13 S2 p. S81-
1 p.
artikel
413 1.167 PRODEST – Depressive symptoms in Parkinson's disease: Pattern across scales Barone, P.
2007
13 S2 p. S51-
1 p.
artikel
414 3.501 Profiling subgroups of cognitive performance in Parkinson's disease van Rooden, S.
2007
13 S2 p. S187-
1 p.
artikel
415 2.320 Protein expression levels and activity of the glial glutamate transporters in the substantia nigra pars reticulata and striatum of 6-hydroxydopamine hemi-Parkinson rats Massie, A.
2007
13 S2 p. S126-S127
2 p.
artikel
416 2.416 Proteomic analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice Diedrich, M.
2007
13 S2 p. S131-S132
2 p.
artikel
417 3.407 Provision of community services for people with Parkinson's disease: A qualitative study of patient and carer perceptions Baker, M.
2007
13 S2 p. S181-S182
2 p.
artikel
418 3.503 Psychiatric symptoms in Parkinson's disease Verbaan, D.
2007
13 S2 p. S188-
1 p.
artikel
419 1.164 Psychiatric symptoms in Parkinson's disease: An assessment in 486 Italian patients Siri, C.
2007
13 S2 p. S50-
1 p.
artikel
420 1.163 Psychomotor retardation in depression: Bradykinesia or paucity of movement? Aybek, S.
2007
13 S2 p. S50-
1 p.
artikel
421 2.437 Purification of nitrated proteins in an organotypic ventral mesencephalon culture model of Parkinson's disease Larsen, T.R.
2007
13 S2 p. S137-
1 p.
artikel
422 3.411 Quality indicators for physiotherapy in Parkinson's disease Munneke, M.
2007
13 S2 p. S183-
1 p.
artikel
423 1.137 Quality of life related to sleep disorders in Parkinson's disease Mihailescu, G.
2007
13 S2 p. S43-
1 p.
artikel
424 1.147 Quantitative analysis of the finger-tapping test in Parkinson's disease by accelerometer Yokoe, M.
2007
13 S2 p. S45-
1 p.
artikel
425 3.117 Raclopride PET in the differential diagnosis of multiple system atrophy and Parkinson's disease using discriminant analysis Clerinx, K.
2007
13 S2 p. S157-S158
2 p.
artikel
426 2.216 Rasagiline in daily clinical use – a post-marketing observational study in Parkinsonian patients receiving combination therapy shows good efficacy and tolerability Reichmann, H.
2007
13 S2 p. S102-
1 p.
artikel
427 1.168 Recognising depression in Parkinson's disease – a problem never solved: Observational study from Split, Croatia Bilic, I.
2007
13 S2 p. S51-
1 p.
artikel
428 1.193 Recognition of gradually revealed objects and sustained attention in Parkinson's disease patients with visual hallucinations Meppelink, A.M.
2007
13 S2 p. S58-
1 p.
artikel
429 2.423 Redox modification of protein kinase B: Implications for neurodegeneration in Parkinson's disease Durgadoss, L.
2007
13 S2 p. S133-S134
2 p.
artikel
430 3.208 Refinement of target position and optimizing position for test stimulation with microrecording during DBS neurosurgery Bour, L.
2007
13 S2 p. S164-
1 p.
artikel
431 3.113 Regional cerebral perfusion abnormalities in patients with diabetic chorea: Statistical parametric mapping analysis Jeong, S.-C.
2007
13 S2 p. S156-
1 p.
artikel
432 2.021 Regulation of the iron-responsive proteins amyloid precursor protein and alpha-synuclein by green tea polyphenol (−)-epigallocatechin-3-gallate Reznichenko, L.
2007
13 S2 p. S91-
1 p.
artikel
433 2.317 Regulation of the iron-responsive proteins amyloid precursor protein and alpha-synuclein by green tea polyphenol (−)-epigallocatechin-3-gallate Reznichenko, L.
2007
13 S2 p. S126-
1 p.
artikel
434 1.203 Relations between homocysteine and cognitive dysfunction in Parkinson's disease Kowa, H.
2007
13 S2 p. S61-
1 p.
artikel
435 2.241 Relationship between awake time spent “off” and systemic exposure of ropinirole 24-hour prolonged release in patients with advanced Parkinson's disease Tompson, D.
2007
13 S2 p. S109-
1 p.
artikel
436 1.015 Relationship between motor symptoms and subtypes of mild cognitive impairment in Parkinson's disease Petrova, M.
2007
13 S2 p. S31-
1 p.
artikel
437 1.186 Relationship between motor symptoms and subtypes of mild cognitive impairment in Parkinson's disease Petrova, M.
2007
13 S2 p. S56-
1 p.
artikel
438 2.242 Relationship between Unified Parkinson's disease Rating Scale total motor score and systemic exposure of ropinirole 24-hour prolonged release in patients with early stage Parkinson's disease Tompson, D.
2007
13 S2 p. S109-
1 p.
artikel
439 1.501 Relationship between weight, levodopa dose and dyskinesia: Hypothesis testing in ropinole versus levodopa in early Parkinson's disease trial data Sharma, J.
2007
13 S2 p. S83-S84
2 p.
artikel
440 3.120 Relevance of combined [18F] FDG PET and [123I] FP-CIT SPECT in the differentiation between multiple system atrophy and Parkinson's disease Eusebio, A.
2007
13 S2 p. S158-
1 p.
artikel
441 1.140 REM sleep behavior disorder in Korean patients with Parkinson disease Sohn, Y.H.
2007
13 S2 p. S43-S44
2 p.
artikel
442 3.245 Repetitive transcranial magnetic stimulation of postcentral sulcus – new treatment method of writer's cramp? Havránková, P.
2007
13 S2 p. S174-
1 p.
artikel
443 1.286 Restless legs syndrome in Korean patients with Parkinson disease Lee, J.E.
2007
13 S2 p. S72-
1 p.
artikel
444 2.448 Reversal of motor deficits without dyskinesia induction by continuous delivery of ropinirole in MPTP-treated common marmosets Stockwell, K.
2007
13 S2 p. S140-
1 p.
artikel
445 1.326 Reversible general paresis and hippocampus hyperintensities after intensive neurosyphilis treatment: A case report Fabiani, G.
2007
13 S2 p. S83-
1 p.
artikel
446 2.502 RGS9−2 negatively modulates L-dopa-induced dyskinesia in experimental Parkinson's disease Bezard, E.
2007
13 S2 p. S143-
1 p.
artikel
447 1.162 Risk factor of mental disorders in Parkinson disease Bolokadze, L.
2007
13 S2 p. S49-S50
2 p.
artikel
448 1.178 Risk factors for psychosis in Parkinson disease Sawada, H.
2007
13 S2 p. S53-S54
2 p.
artikel
449 1.204 Rivastigmin (Exelon) for non demented Parkinson patients with hallucinations: A single center experience under real life conditions Kohler, J.
2007
13 S2 p. S61-
1 p.
artikel
450 2.004 RLS-PLMS Trenkwalder, C.
2007
13 S2 p. S87-S88
2 p.
artikel
451 2.111 RNA binding targets of the recessive parkinsonism protein DJ-1 reveals involvement in mitochondrial, oxidative stress and PTEN/Akt survival pathways van der Brug, M.
2007
13 S2 p. S95-
1 p.
artikel
452 2.501 Role of DeltaFosB in the development of L-DOPA-induced dyskinesia in a non-human primate model of Parkinson's disease Bezard, E.
2007
13 S2 p. S142-
1 p.
artikel
453 2.235 Ropinirole and pramipexole: Antinociceptive effects in a rat model of pain perception, pharmacological effect or behavioral competition? McCreary, A.
2007
13 S2 p. S107-
1 p.
artikel
454 1.293 Ropinirole CR improves the symptoms of restless legs syndrome from the first night of treatment Bogan, R.
2007
13 S2 p. S74-
1 p.
artikel
455 1.296 Ropinirole CR reduces sleep disturbance in patients with moderate-to-severe primary restless legs syndrome: Results from a 12-week pivotal study Bogan, R.
2007
13 S2 p. S75-
1 p.
artikel
456 1.295 Ropinirole CR significantly improves quality of life in patients with restless legs syndrome Bogan, R.
2007
13 S2 p. S75-
1 p.
artikel
457 2.238 Ropinirole 24-hour prolonged-release adjunctive therapy improves cardinal symptoms in patients with advanced Parkinson's disease not optimally controlled with L-dopa Isaacson, S.
2007
13 S2 p. S108-
1 p.
artikel
458 2.243 Ropinirole 24-hour prolonged release improves mood and quality of life in patients with advanced Parkinson's disease as adjunctive therapy Stocchi, F.
2007
13 S2 p. S109-
1 p.
artikel
459 2.237 Ropinirole 24-hour prolonged release improves sleep disturbance, but does not increase daytime somnolence in patients with advanced Parkinson's disease when administered as adjunctive therapy Isaacson, S.
2007
13 S2 p. S108-
1 p.
artikel
460 2.236 Ropinirole used as an adjunct to levodopa is effective on motor function in Parkinson's disease Oztekin, N.
2007
13 S2 p. S107-
1 p.
artikel
461 1.297 Rotigotine transdermal patch is effective in the treatment of idiopathic RLS: Results of a 6 month, multicenter, double blind, placebo controlled trial in Europe Trenkwalder, C.
2007
13 S2 p. S75-S76
2 p.
artikel
462 2.247 Safe and tolerable switching from oral dopaminergic agonists to transdermal rotigotine in Parkinson's disease LeWitt, P.
2007
13 S2 p. S110-S111
2 p.
artikel
463 2.207 Safinamide: Beyond MAO-B inhibition Caccia, C.
2007
13 S2 p. S99-
1 p.
artikel
464 2.208 Safinamide potentiates the effects of dopamine (DA)-agonists in early stage Parkinson's disease patients Borgohain, R.
2007
13 S2 p. S99-
1 p.
artikel
465 3.508 SCOPA-COG Brazilian Version: psychometric attributes Martinez-Martin, P.
2007
13 S2 p. S189-
1 p.
artikel
466 1.197 Sequence learning and the basal ganglia Ghilardi, M.F.
2007
13 S2 p. S59-
1 p.
artikel
467 1.267 Serial MRI imaging in extra-pontine myelinolysis – the MRI improves, but the patient worsens Gontu, V.
2007
13 S2 p. S69-
1 p.
artikel
468 2.425 Serum Cu, Fe, Mn and Zn levels and Parkinson's disease Tan, X.
2007
13 S2 p. S134-
1 p.
artikel
469 1.160 Serum leptin and ghrelin concentrations in Parkinson's disease patients with and without weight loss Fiszer, U.
2007
13 S2 p. S49-
1 p.
artikel
470 1.181 Serum prolactin, leptin, lipids and lipoproteins levels during long-term antipsychotics treatment in Parkinson's disease related psychosis Rustembegovic, A.
2007
13 S2 p. S54-
1 p.
artikel
471 3.116 Set-shifting deficit and fronto-temporal hypometabolism in early Parkinson's disease Polito, C.
2007
13 S2 p. S157-
1 p.
artikel
472 2.405 Severe damage of mitochondria in Parkinson's disease transgenics Linnartz, B.
2007
13 S2 p. S128-
1 p.
artikel
473 2.285 Severe lymphedema in a patient with Parkinson's disease using pramipeloxe: A case report Munhoz, R.
2007
13 S2 p. S121-
1 p.
artikel
474 1.143 Sex and Parkinson's disease Kawulak-Król, M.
2007
13 S2 p. S44-
1 p.
artikel
475 1.323 Siblings of SCA type 2 with heterogenous neurodegenerative disorders Yabe, H.
2007
13 S2 p. S82-S83
2 p.
artikel
476 2.401 Silencing plus over expression of selected genes as a novel model of sporadic Parkinson's disease Fishman, T.
2007
13 S2 p. S127-
1 p.
artikel
477 1.153 Silent aspiration in Parkinson's disease patients with diurnal sialorrhea Nóbrega, A.C.
2007
13 S2 p. S47-
1 p.
artikel
478 1.258 Singing-induced cervical dystonia Fabiani, G.
2007
13 S2 p. S67-
1 p.
artikel
479 1.169 Sleep disorders and depression among black Parkinson's disease patients: A study of 37 patients in University of Maiduguri Teaching Hospital Nyandaiti, Y.
2007
13 S2 p. S51-
1 p.
artikel
480 1.139 Sleep disturbance and daytime sleepiness in Flemish persons with Parkinson's disease Kerckhofs, E.
2007
13 S2 p. S43-
1 p.
artikel
481 1.141 Sleep quality in Parkinson's disease patients with depression Smiljkovic, T.
2007
13 S2 p. S44-
1 p.
artikel
482 1.136 Sleep-related problems in patients with Parkinson's disease Lee, H.-W.
2007
13 S2 p. S42-S43
2 p.
artikel
483 1.303 Social prognosis of attention deficit/hyperactivity disorder (ADHD) in late- and post-adolescence based on the ability to adapt under the conditions of military service in the German Armed Forces Jenuwein, M.
2007
13 S2 p. S77-
1 p.
artikel
484 1.005 Solving sexual problems in movement disorders Bronner, G.
2007
13 S2 p. S30-
1 p.
artikel
485 3.015 Sonographic evaluation of substantia nigra in parkinsonian syndromes Bartova, P.
2007
13 S2 p. S149-
1 p.
artikel
486 3.123 Sonographic evaluation of substantia nigra in parkinsonian syndromes Bartova, P.
2007
13 S2 p. S159-
1 p.
artikel
487 1.183 SPAARS approach: A new theoretical framework for self-injurious behavior Khetrapal, N.
2007
13 S2 p. S55-
1 p.
artikel
488 3.229 Speech before and after DBS in STN surgery: The view of the patients and their spouses Törnqvist, A.L.
2007
13 S2 p. S169-S170
2 p.
artikel
489 3.228 Speech outcome following one year of bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease: Results from a consecutive prospective study of thirty patients Tripoliti, E.
2007
13 S2 p. S169-
1 p.
artikel
490 1.320 Spinocerebellar ataxia type 10: Frequency of epilepsy in a large sample of Brazilian patients Munhoz, R.
2007
13 S2 p. S82-
1 p.
artikel
491 1.127 Spontaneous observation saccades in Parkinson's disease Sienkiewicz, J.
2007
13 S2 p. S40-
1 p.
artikel
492 2.240 Steady-state pharmacokinetics of ropinirole 24-hour prolonged release: Relative bioavailability and food effect in patients with Parkinson's disease Vearer, D.
2007
13 S2 p. S108-S109
2 p.
artikel
493 1.105 Stressful life events and Parkinson's disease: A case-control study Sipetic-Grujicic, S.
2007
13 S2 p. S35-
1 p.
artikel
494 1.171 Study of the prevalence of depression among patients with Parkinson's disease Riccioppo, G.
2007
13 S2 p. S52-
1 p.
artikel
495 1.173 Study of the validation of the Zung, PHQ-9 and GDS-15 scales of major depression in patients with Parkinson's disease Riccioppo, G.
2007
13 S2 p. S52-S53
2 p.
artikel
496 2.102 Sub-cellular localization studies of LRRK2, a brain-specific protein Schweiger, D.
2007
13 S2 p. S92-
1 p.
artikel
497 1.192 Subtle executive dysfunction in early Parkinson's disease: A case-control study Hipp, G.
2007
13 S2 p. S57-
1 p.
artikel
498 2.280 Suppression of L-DOPA induced dyskinesias in advanced Parkinson's disease by continuous subcutaneous infusions of apomorphine – ten years of experience Kanovsky, P.
2007
13 S2 p. S119-S120
2 p.
artikel
499 2.444 Suppression of neurotoxicity by antioxidant molecules in cellular models of Parkinson's disease Strathearn, K.
2007
13 S2 p. S139-
1 p.
artikel
500 3.218 Surgical treatment improving quality of life in Parkinson's disease Singh, A.
2007
13 S2 p. S166-
1 p.
artikel
501 3.018 Survival and host immune response of implants of human retinal pigment epithelial cells on gelatin microcarriers (hRPE-GM) (Spheramine®) in animal models of Parkinson's disease (PD) Flores, J.
2007
13 S2 p. S150-
1 p.
artikel
502 3.202 Survival and host immune response of implants of human retinal pigment epithelial cells on gelatin microcarriers (hRPE-GM) (Spheramine®) in animal models of Parkinson's disease (PD) Flores, J.
2007
13 S2 p. S161-S162
2 p.
artikel
503 1.263 Symptoms accompanying hemifacial spasm Wojcik, M.
2007
13 S2 p. S68-
1 p.
artikel
504 1.114 Taste disorders in Parkinson's disease and parkinsonian syndromes Lang, C.
2007
13 S2 p. S37-
1 p.
artikel
505 2.260 TEAM: A French cross-sectional study on the time-related evolution of the scores of the “Handipark”, in relation to the duration of the Parkinson's disease Ziegler, M.
2007
13 S2 p. S114-
1 p.
artikel
506 1.145 Testosteron levels, fatigue and apathy in Parkinson's disease Kenangil, G.
2007
13 S2 p. S45-
1 p.
artikel
507 3.402 The Activities of Daily Living (ADL) taxonomy provides an individualized profile of disability in patients with Parkinson's disease Hariz, G.-M.
2007
13 S2 p. S180-
1 p.
artikel
508 1.261 The clinical characteristics of dystonic tremor syndromes Hawkes, E.
2007
13 S2 p. S68-
1 p.
artikel
509 3.410 The development and evaluation of an electronic patient record for physiotherapy in Parkinson's disease Munneke, M.
2007
13 S2 p. S182-
1 p.
artikel
510 2.233 The effectiveness of pramipexole and cabergoline as an adjunct to levodopa in Parkinson's disease Oztekin, N.
2007
13 S2 p. S106-S107
2 p.
artikel
511 2.256 The effect of isradipine on Parkinson's disease: A retrospective study in Korea Kim, W.-C.
2007
13 S2 p. S113-
1 p.
artikel
512 3.422 The effect of motor fluctuations on Parkinson's disease patient Quality of Life and the potential benefits of apomorphine continuous infusion Bosanquet, N.
2007
13 S2 p. S185-S186
2 p.
artikel
513 1.198 The effect of Parkinson's disease on implicit spatial context learning van Asselen, M.
2007
13 S2 p. S59-
1 p.
artikel
514 2.229 The effect of pergolide and pramipexole on Parkinson tremor in patients with early Parkinson's disease Oztekin, N.
2007
13 S2 p. S105-
1 p.
artikel
515 2.427 The effect of p38 inhibition on the survival of 6-hydroxydopamine-treated rat ventral mesencephalic neurons in vitro Long, C.
2007
13 S2 p. S134-
1 p.
artikel
516 3.021 The effect of repetitive transcranial magnetic stimulation on intracranial recordings of event related potentials in patients with Parkinson's disease Balaz, M.
2007
13 S2 p. S151-
1 p.
artikel
517 3.246 The effect of repetitive transcranial magnetic stimulation on intracranial recordings of event related potentials in patients with Parkinson's disease Balaz, M.
2007
13 S2 p. S174-S175
2 p.
artikel
518 2.265 The effect of subchronic, intermittent L-DOPA treatment on nNOS and sCG expression and activity in the striatum and midbrain of normal and MPTP-treated mice Chalimoniuk, M.
2007
13 S2 p. S115-S116
2 p.
artikel
519 3.223 The effects of bilateral subthalamic nucleus stimulation on executive functions in patients with Parkinson's disease Kaiser, I.
2007
13 S2 p. S168-
1 p.
artikel
520 2.318 The effects of melanin on alpha-synuclein over-expressing dopaminergic cells Li, J.
2007
13 S2 p. S126-
1 p.
artikel
521 3.417 The effects of pharmacological treatment on speech in Parkinson's disease Santens, P.
2007
13 S2 p. S184-
1 p.
artikel
522 3.226 The frequency and magnitude of impulse control deficits in Parkinson's disease patients with deep brain stimulation of the subthalamic nucleus Tse, W.
2007
13 S2 p. S168-S169
2 p.
artikel
523 2.282 The frequency of cardiac valve regurgitation in Japanese patients with Parkinson's disease using cabergoline Sekiguchi, T.
2007
13 S2 p. S120-
1 p.
artikel
524 2.283 The frequency of cardiac valve regurgitation in Japanese patients with Parkinson's disease using pergolide Kimura, K.
2007
13 S2 p. S120-
1 p.
artikel
525 2.508 The HMG-CoA reductase inhibitor lovastatin reduces incidence of L-Dopa-induced abnormal involuntary movements in experimental Parkinson's disease Schuster, S.
2007
13 S2 p. S144-
1 p.
artikel
526 2.454 The immunosuppressant, 4-deoxypyridoxine (DOP), demonstrates novel neuroprotective effects in the acute MPTP model of Parkinson's disease Baquet, Z.
2007
13 S2 p. S142-
1 p.
artikel
527 3.421 The impact of Parkinson's disease age at onset on quality of life: its effect on non-motor symptoms Klepac, N.
2007
13 S2 p. S185-
1 p.
artikel
528 2.434 The impact of the glutamatergic manipulations on the aminoacid neurotransmitter release in pedunculopontine nucleus of hemiparkinsonian rats Blanco-Lezcano, L.
2007
13 S2 p. S136-
1 p.
artikel
529 3.207 The impact of the use of Access Therapy Controller on the postoperative outcome Kovacs, N.
2007
13 S2 p. S163-
1 p.
artikel
530 2.104 The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation: Association with Parkinson's disease and malignant melanoma Molchadski, I.
2007
13 S2 p. S93-
1 p.
artikel
531 2.014 The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation: Association with Parkinson's disease and malignant melanoma Molchadski, I.
2007
13 S2 p. S89-
1 p.
artikel
532 3.408 The level of physical activity in patients with Parkinson's disease Munneke, M.
2007
13 S2 p. S182-
1 p.
artikel
533 2.114 The “Lister family”: An extended pedigree with alpha-synuclein multiplications and Parkinson's disease Puschmann, A.
2007
13 S2 p. S95-S96
2 p.
artikel
534 2.305 The mechanism of alpha-synuclein fibril formation studied with high resolution Atomic Force Microscopy Segers-Nolten, I.
2007
13 S2 p. S122-S123
2 p.
artikel
535 1.176 The neuropathological basis for depression in Parkinson's disease Frisina, P.
2007
13 S2 p. S53-
1 p.
artikel
536 2.442 The neuroprotective effect of smoking in Parkinson's disease: Re-analysis of the structural effects realised by tar components (MEP) Mititelu, A.G.
2007
13 S2 p. S139-
1 p.
artikel
537 1.251 The optimal settings of pallidal deep brain stimulation for DYT1-positive primary generalized dystonia Okiyama, R.
2007
13 S2 p. S65-
1 p.
artikel
538 1.132 The origin of pain phenomena in Parkinson's disease Albu, S.
2007
13 S2 p. S41-S42
2 p.
artikel
539 2.433 The possibility of kynurenine metabolites binding to ionotropic glutamate receptors and to calmodulin: data on molecular modeling and Drosophila kynurenic mutants Zhuravlev, A.
2007
13 S2 p. S136-
1 p.
artikel
540 1.188 The prevalence of cognitive and affective infringements at patients with Parkinson's disease and essential tremor in Krasnoyarsk's region: A pilot study Pokhabov, D.
2007
13 S2 p. S56-
1 p.
artikel
541 2.432 Therapeutic activity of short synthetic peptides Cortagen and Livagen in Drosophila model for neurodegenerative disorders facilitated by heat shock in mutants of kynurenine pathway Savvateeva-Popova, E.
2007
13 S2 p. S136-
1 p.
artikel
542 1.276 Therapeutic opportunities for treatment of essential tremor Zalyalova, Z.
2007
13 S2 p. S70-
1 p.
artikel
543 1.191 The relationship between executive and motor functioning in patients with Parkinson's disease Olzak, M.
2007
13 S2 p. S57-
1 p.
artikel
544 1.158 The relationship between Parkinson's disease and nutritional status Tan, X.
2007
13 S2 p. S48-S49
2 p.
artikel
545 3.309 The repeatability of standardised movement analysis of people with Parkinson's disease in the home and the gait lab Roberts, H.
2007
13 S2 p. S177-S178
2 p.
artikel
546 2.277 The role of apolipoprotein E polymorphisms in the development of levodopa-induced dyskinesia in Parkinson's disease Molchadski, I.
2007
13 S2 p. S119-
1 p.
artikel
547 2.419 The role of cGMP dependent protrin kinese in cytosolic PLA2 phosphorylation and AA release in primary astrocytes exposed 1-methyl-4-phenylpyridinium (MPP+) Stolecka, A.
2007
13 S2 p. S132-
1 p.
artikel
548 2.211 The SENSE study: An open-label, single-arm, multicentre, 6-week study evaluating the efficacy and safety of levodopa/carbidopa/entacapone (Stavelo) in Parkinson's disease patients experiencing early re-emergence of symptoms due to wearing-off with conventional medication Oertel, W.H.
2007
13 S2 p. S100-
1 p.
artikel
549 2.506 The severity of L-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents Rylander, D.
2007
13 S2 p. S144-
1 p.
artikel
550 2.016 The severity of L-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents Rylander, D.
2007
13 S2 p. S90-
1 p.
artikel
551 3.213 The SunMed Deep Brain Stimulation Programme for Parkinson's disease: Review after four years Lee, M.K.
2007
13 S2 p. S165-
1 p.
artikel
552 1.131 The tecto-subthalamic projection: A source of short-latency visual input to the subthalamic nucleus Coizet, V.
2007
13 S2 p. S41-
1 p.
artikel
553 1.182 The Ten Euro Neurotest (TEN): A new reliable and valid bedside test of dexterity in patients with Parkinson's disease van Vugt, J.P.
2007
13 S2 p. S55-
1 p.
artikel
554 1.264 The treatment of dystonic tremor syndromes Hawkes, E.
2007
13 S2 p. S68-S69
2 p.
artikel
555 2.261 The use of client-centred assessment in Parkinson's disease Jansa, J.
2007
13 S2 p. S114-
1 p.
artikel
556 3.129 The whole-body startle reflex in children with anxiety disorders Bakker, M.
2007
13 S2 p. S160-S161
2 p.
artikel
557 2.408 Time course of amyloid beta pathology in streptozotocin-rat model of sporadic Alzheimer's Disease Salkovic-Petrisic, M.
2007
13 S2 p. S129-
1 p.
artikel
558 1.202 Time estimation in patients with Parkinson's disease and Friedreich's ataxia Beudel, M.
2007
13 S2 p. S60-S61
2 p.
artikel
559 2.429 Tissue transglutaminase is activated and redistributed to ER-derived granules in neuroblastoma cells treated with the PD-mimicking neurotoxin MPP+ Wilhelmus, M.
2007
13 S2 p. S135-
1 p.
artikel
560 2.214 Tolcapone treatment fluctuating patients with Parkinson's disease who did not benefit from entacapone Canesi, M.
2007
13 S2 p. S101-
1 p.
artikel
561 1.294 Tolerability with no loss of efficacy after overnight conversion from immediate-release ropinirole to an extended-release formulation – ropinirole CR – in restless legs syndrome Isaacson, S.
2007
13 S2 p. S74-S75
2 p.
artikel
562 4.003 Towards the molecular understanding of PD by applying proteomic approaches Meyer, H.
2007
13 S2 p. S192-
1 p.
artikel
563 1.103 Toxic substance exposure and chracteristics of Parkinson's disease Budisic, M.
2007
13 S2 p. S34-
1 p.
artikel
564 1.021 Training cortical networks in attention deficit disorder Baijal, S.
2007
13 S2 p. S32-S33
2 p.
artikel
565 1.302 Training cortical networks in attention deficit disorder Baijal, S.
2007
13 S2 p. S77-
1 p.
artikel
566 2.005 Transcranial magnetic stimulation van der Werf, Y.
2007
13 S2 p. S88-
1 p.
artikel
567 3.126 Transcranial sonography and Parkinson disease Bolokadze, L.
2007
13 S2 p. S160-
1 p.
artikel
568 3.125 Transcranial sonography in evaluation of patients with movement disorders Crnjakovic, M.
2007
13 S2 p. S159-S160
2 p.
artikel
569 2.105 Transcriptome profiling in peripheral blood cells of LRRK2 G2019S mutation patients Mutez, E.
2007
13 S2 p. S93-
1 p.
artikel
570 1.298 Transdermal lisuride in patients with idiopathic restless legs syndrome: Results from a placebo-controlled, double-blind 12-week dose-finding study with a 48-week open-label extension phase Benes, H.
2007
13 S2 p. S76-
1 p.
artikel
571 3.423 Travelling related worsening of parkinsonism in Parkinson's disease Naidu, Y.
2007
13 S2 p. S186-
1 p.
artikel
572 2.246 Treatment of early morning and night time motor symptoms with rotigotine transdermal system in Parkinson's disease patients Giladi, N.
2007
13 S2 p. S110-
1 p.
artikel
573 1.180 Treatment of psychosis in Parkinson's disease with atypical antipsychotics Leotsakou, C.
2007
13 S2 p. S54-
1 p.
artikel
574 4.004 Tremor Bain, P.
2007
13 S2 p. S192-
1 p.
artikel
575 1.306 Two novel epsilon-sarcoglycan mutations within one patient with myoclonus–dystonia Ritz, K.
2007
13 S2 p. S78-
1 p.
artikel
576 3.306 Two simple clinical postural instability tests and their ability to predict fallers and non-fallers in subjects with Parkinson's disease Valkovic, P.
2007
13 S2 p. S177-
1 p.
artikel
577 1.313 Unified Wilson's Disease Rating Scale (UWDRS) – a proposal for the neurological scoring of Wilson's disease patients Czlonkowska, A.
2007
13 S2 p. S80-
1 p.
artikel
578 3.234 Unilateral deep brain stimulation of thalamic nuclei for treatment of intractable tremor of Parkinson's disease Singh, A.
2007
13 S2 p. S171-
1 p.
artikel
579 3.239 Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation Munhoz, R.
2007
13 S2 p. S172-
1 p.
artikel
580 3.233 Unilateral stimulation of subthalamic nucleus for Parkinson disease Kajita, Y.
2007
13 S2 p. S170-S171
2 p.
artikel
581 2.415 Use of an optimized striatal and medial forebrain bundle 6-hydroxydopamine rat model for Parkinson's disease in the search for neuroprotective drugs Mertens, B.
2007
13 S2 p. S131-
1 p.
artikel
582 2.202 Use of dopamine agonists and levodopa in Germany: Do German neurologists adhere to national Parkinson guidelines? Schröder, S.
2007
13 S2 p. S98-
1 p.
artikel
583 2.424 Variation of magnesium levels in RBC and extracelluar fluid of midbrain substantia nigra of rat model of Parkinson's disease Luo, Y.
2007
13 S2 p. S134-
1 p.
artikel
584 2.428 VEGF and angiogenesis in an animal model of Parkinson's disease Smeyne, M.
2007
13 S2 p. S135-
1 p.
artikel
585 1.260 Venlafaxine-induced bruxism Alonso Navarro, H.
2007
13 S2 p. S67-
1 p.
artikel
586 1.130 Visual electrophysiology in Parkinson's disease: Relation to clinical and functional impairments Osman Achmawi, G.A.
2007
13 S2 p. S41-
1 p.
artikel
587 1.201 Visuospatial and visuoconstructive impairment effects in neuropsychological assessment in patients with Parkinson's disease Marañon, D.
2007
13 S2 p. S60-
1 p.
artikel
588 2.273 Wearing-off management in Parkinson's disease: The LEVOSTAR study Rerat, K.
2007
13 S2 p. S117-S118
2 p.
artikel
589 2.270 “Wearing off” Questionnaire in early-onset and late-onset Parkinson's disease Telarovic, S.
2007
13 S2 p. S117-
1 p.
artikel
590 2.271 Wearing-off symptoms in Parkinson's disease – the patient perspective: A nationwide survey in Norway Alves, G.
2007
13 S2 p. S117-
1 p.
artikel
591 1.159 Weight loss and adiponectin levels in patients with Parkinson's disease Tsuboi, Y.
2007
13 S2 p. S49-
1 p.
artikel
592 Welcome addresses Wolters, Erik Ch.
2007
13 S2 p. xiii-xiv
nvt p.
artikel
593 3.217 What influences the quality of life in Parkinsonian patients after subthalamic DBS? Tamma, F.
2007
13 S2 p. S166-
1 p.
artikel
594 What you always wanted to know about … Early Markers in PD W. Berendse, Henk
2007
13 S2 p. S92-
1 p.
artikel
595 What you always wanted to know about … Genetics Hardy, John
2007
13 S2 p. S92-
1 p.
artikel
596 What you always wanted to know about… Lewy Bodies McKeith, Ian
2007
13 S2 p. S33-
1 p.
artikel
597 What you always wanted to know about … Medical history Goldman, Jennifer
2007
13 S2 p. S152-
1 p.
artikel
598 What you always wanted to know about… The hottest topics Franz, Peter
2007
13 S2 p. S33-
1 p.
artikel
599 What you always wanted to know about … The newest therapeutical strategies Antonini, Angelo
2007
13 S2 p. S152-
1 p.
artikel
600 1.110 Women do better in health and disease: Olfactory function in Parkinson's disease patients differs according to gender Strothjohann, M.H.
2007
13 S2 p. S36-
1 p.
artikel
601 1.200 Word processing in Parkinson's disease is impaired for action verbs but not for concrete nouns Thobois, S.
2007
13 S2 p. S60-
1 p.
artikel
602 1.256 Xeroderma Pigmentosum with neurological manifestations: 2 observations Thobois, S.
2007
13 S2 p. S66-S67
2 p.
artikel
603 3.017 Zuckerkandl's organ improves long-term survival and function of neural stem cells derived dopaminergic neurons in Parkinsonian rats Chaturvedi, R.K.
2007
13 S2 p. S150-
1 p.
artikel
604 3.204 Zuckerkandl's organ improves long-term survival and function of neural stem cells derived dopaminergic neurons in Parkinsonian rats Chaturvedi, R.K.
2007
13 S2 p. S162-S163
2 p.
artikel
                             604 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland